pseudotumor cerebri

Complex MONDO:0009468 Pathograph 34 Show in embeddings browser disease intracranial hypertension

Pseudotumor cerebri syndrome is elevated intracranial pressure without a mass lesion, hydrocephalus, or abnormal CSF composition. This entry primarily models idiopathic intracranial hypertension (IIH), after secondary causes are excluded. Its mechanisms include altered CSF secretion and outflow and intracranial venous hypertension on a metabolic background strongly associated with obesity. Their causal ordering is unresolved and can differ between patients. Headache, papilledema, transient visual obscurations, visual field loss, and pulsatile tinnitus dominate the clinical presentation; persistent optic nerve injury can cause permanent visual loss.

Ask OpenScientist

Ask a research question about pseudotumor cerebri. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

13
Pathophys.
10
Phenotypes
3
Hypotheses
6
Gaps
34
Pathograph
10
Medical Actions
3
Differentials
5
Trials
3
Models
2
References
1
Deep Research
1
Hyp. Reports
◈

Mechanistic Hypotheses

3
Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
choroid_plexus_csf_hypersecretion EMERGING
Evidence balance 5 support
Metabolic and hormonal abnormalities may contribute to raised ICP through choroid plexus secretion in a subset of IIH. Human androgen excess and rodent perturbations support plausibility, but direct human secretion measurements and causal ordering remain unresolved. GLP-1 receptor agonism suppresses secretory transport in preclinical systems and lowers ICP in a small randomized trial; endogenous GLP-1 deficiency has not been established. The AZD4017 trial did not meet its primary between-group endpoint. Impaired outflow, intrinsic venous lesions, and pressure-dependent venous feedback may act in parallel or dominate in other patients.
Retain EMERGING. OpenScientist correctly argues against promoting a single primary hypersecretion model, but overstates several supporting claims: chronic testosterone activated NKCC1 rather than Na+/K+-ATPase in PMID:37328884, intrinsic stenosis proportions come from a selected stenting cohort, and pharmacological response does not establish the untreated initiating lesion. The assessment sidecar records these and other source-level qualifications.
Pathograph links
Metabolic risk background -> Androgen excess INDIRECT UNKNOWN INTERMEDIATES A distinct androgen profile accompanies the metabolic phenotype of adult women with IIH; the causal coupling remains hypothetical.
Metabolic risk background -> Altered glucocorticoid metabolism INDIRECT UNKNOWN INTERMEDIATES Elevated systemic and adipose 11β-HSD1 activity accompanies active IIH, but causal mediation is unresolved.
Metabolic risk background -> Impaired cerebrospinal fluid outflow INDIRECT KNOWN INTERMEDIATES High-fat feeding can increase drainage resistance in rats; the corresponding human metabolic-to-outflow mechanism remains unconfirmed.
Choroid plexus CSF hypersecretion -> Dysregulated cerebrospinal fluid dynamics INDIRECT KNOWN INTERMEDIATES Higher secretion can shift fluid balance when outflow compensation is insufficient.
Androgen excess -> Choroid plexus CSF hypersecretion INDIRECT KNOWN INTERMEDIATES Testosterone can enhance choroid plexus transport and secretion in rodent models; extrapolation to human IIH remains emerging.
Altered glucocorticoid metabolism -> Dysregulated cerebrospinal fluid dynamics INDIRECT KNOWN INTERMEDIATES Glucocorticoid metabolism is proposed to influence secretion and/or drainage structures; association and target engagement do not establish mediation.
Deep research
OpenScientist citations 41 citations 2026-06-04T08:50:25.512404
Show evidence (5 references)
PMID:30753168 SUPPORT Human Clinical
"Women with IIH showed a pattern of androgen excess distinct to that observed in PCOS and simple obesity, with increased serum testosterone and increased CSF testosterone and androstenedione."
Human steroid profiling demonstrates an association in adult women; it does not establish that androgen excess initiates raised pressure.
PMID:37328884 SUPPORT Model Organism
"Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%) and CSF secretion rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter, NKCC1."
Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated mechanism; human IIH secretion was not measured.
PMID:36907221 SUPPORT Human Clinical
"Exenatide significantly and meaningfully lowered intracranial pressure at 2.5 h -5.7 ± 2.9 cmCSF (P = 0.048); 24 h -6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks -5.6 ± 3.0 cmCSF (P = 0.058)."
The small randomized trial supports ICP lowering; alpha was prespecified at 0.1 and direct CSF secretion was not measured.
+ 2 more references
Primary Venous Sinus Obstruction Model
primary_venous_sinus_obstruction ALTERNATIVE
Evidence balance 1 support
A venous contribution can arise from intrinsic transverse-sigmoid narrowing or pressure-dependent extrinsic compression. A significant gradient can sustain venous hypertension and impaired CSF outflow, with ICP-dependent narrowing closing a feedback loop. Stenting responses support a modifiable hemodynamic contributor in selected patients but do not establish that venous obstruction initiates every case.
Pathograph links
Venous sinus stenosis -> Intracranial venous hypertension INDIRECT KNOWN INTERMEDIATES A hemodynamically significant narrowing raises upstream venous pressure through a trans-stenotic gradient.
Intracranial venous hypertension -> Impaired cerebrospinal fluid outflow INDIRECT KNOWN INTERMEDIATES Elevated venous back-pressure reduces the pressure gradient available for CSF absorption.
Impaired cerebrospinal fluid outflow -> Dysregulated cerebrospinal fluid dynamics INDIRECT KNOWN INTERMEDIATES Reduced outflow shifts CSF balance toward a raised-pressure state.
Show evidence (1 reference)
PMID:37410913 SUPPORT Other
"Venous sinus stenosis, typically at the junction of the transverse and sigmoid sinus, is increasingly recognized as a contributor to the pathophysiology of idiopathic intracranial hypertension (IIH), whether it be the intrinsic type that does not reverse with normalization of intracranial..."
Intrinsic and pressure-responsive extrinsic lesions are distinct morphologies; persistence alone does not prove that the lesion preceded IIH.
Glymphatic and Interstitial Fluid Dyshomeostasis Model
glymphatic_isf_dyshomeostasis ALTERNATIVE
Evidence balance 2 support
A competing model places the primary fluid disturbance in interstitial fluid clearance rather than in CSF secretion. Obesity-associated metabolic dysfunction is proposed to impair glymphatic clearance, interstitial fluid then accumulates, brain volume rises, and the swollen parenchyma compresses the dural venous sinuses from outside, with the resulting venous hypertension feeding back on glymphatic drainage. It accommodates the rat paradigm in which high-fat feeding raises ICP with the CSF secretion rate unchanged, but it is argued from narrative synthesis and cross-sectional imaging surrogates, and glymphatic function in patients has so far been assessed only through an imaging index rather than measured directly.
Recorded as ALTERNATIVE rather than EMERGING because the mechanism rests on narrative synthesis and correlational imaging surrogates, with no interventional study and no direct clearance measurement in IIH. The hypothesis assessment sidecar dispositions the unifying glymphatic claim as QUALIFIED and asks that it be preserved as an explicit hypothesis rather than a canonical causal chain, which is the form used here. No pathophysiology node asserts impaired glymphatic clearance, so no causal edge opts into this group; separating it from the secretory model needs paired secretion-rate and clearance measurement in the same patients.
Show evidence (2 references)
PMID:41472646 SUPPORT Other
"We propose a unified disease model where obesity-mediated metabolic dysfunction results in impaired glymphatic clearance with consequential accumulation of brain ISF with resultant increased brain volume."
States the alternative causal ordering in the proposing authors' own words. It is a narrative review advancing a framework rather than a primary result, so it establishes that the model is seriously argued in the literature and not that it is correct.
PMID:39585390 SUPPORT INDIRECT Human Clinical
"Additionally, increasing PSAS/ONSD was associated with declining/worsening cerebral glymphatic clearance based on DTI-APLS (p = 0.043, R = 0.34)."
The closest patient-level observation the model currently has: in 55 retrospectively identified IIH patients a marker of perioptic CSF distension tracked a lower DTI-ALPS index. DTI-ALPS is a diffusion surrogate rather than a clearance measurement, the association is weak and cross-sectional, and the same regression associated the marker with larger choroid plexus volume, so it does not separate this model from choroid plexus hypersecretion.
?

Discussions and Knowledge Gaps

6
What is the proximate mechanism of headache in IIH, and why is it imperfectly coupled to the degree of intracranial pressure elevation?
KNOWLEDGE GAP OPEN gap_iih_headache_mechanism
Attached to
pathophysiology#Headache syndrome pathophysiology#CGRP-mediated trigeminovascular headache signaling
Headache is the dominant symptomatic morbidity but its mechanism is only partly understood. Human CGRP provocation data now support trigeminovascular neuropeptide signaling and ICP pulsatility as a proximal mechanism, while headache can still persist or fluctuate independently of measured pressure. Modeling headache purely as a downstream consequence of raised mean pressure remains incomplete.
Is transverse venous sinus stenosis a primary initiating lesion or a pressure-dependent feedback consequence in IIH?
KNOWLEDGE GAP OPEN gap_iih_venous_stenosis_cause_or_consequence
Attached to
pathophysiology#Venous sinus stenosis pathophysiology#Dysregulated cerebrospinal fluid dynamics pathophysiology#Elevated intracranial pressure
Transverse sinus stenosis is present in most patients and venous sinus stenting helps a subset, yet stenosis can reverse once intracranial pressure is lowered. Whether it initiates the disease or amplifies an already-elevated-pressure state is unresolved and distinguishes the primary venous obstruction model from the choroid plexus hypersecretion model.
Why does IIH predominantly affect obese women of reproductive age, and what distinguishes the mechanism in non-obese or atypical cases?
KNOWLEDGE GAP OPEN gap_iih_sex_and_nonobese_predilection
Attached to
pathophysiology#Metabolic risk background pathophysiology#Choroid plexus CSF hypersecretion
Sex and metabolic associations do not explain all IIH presentations. Pediatric, male, and non-obese populations require separate evaluation; medication-related raised ICP is a secondary cause to exclude, not evidence for an idiopathic non-obese subtype.
How do obesity/metabolic-hormonal drivers, venous sinus pressure and stenosis, and CSF production/absorption interact causally in IIH, and which of these is the initiating event versus an amplifying feedback consequence?
KNOWLEDGE GAP OPEN gap_iih_obesity_venous_csf_hierarchy
Attached to
pathophysiology#Metabolic risk background pathophysiology#Choroid plexus CSF hypersecretion pathophysiology#Venous sinus stenosis pathophysiology#Dysregulated cerebrospinal fluid dynamics
IIH is defined by raised intracranial pressure without a mass lesion, yet the causal ordering among its candidate mechanisms remains unresolved. Multiple pathways have been proposed as the underlying cause - choroid plexus CSF overproduction, impaired CSF outflow/absorption, elevated venous sinus pressure with transverse sinus stenosis, glymphatic dysfunction, and obesity-associated hormonal alterations - but no single theory explains the entire clinical picture. The metabolic-hormonal arm is an attractive upstream driver because pharmacological modulation lowers intracranial pressure, yet the AZD4017 trial missed its primary endpoint and the human evidence linking specific hormonal axes to choroid plexus secretion is still maturing. Venous sinus stenosis is present in most patients and stenting helps a subset, but stenosis frequently reverses once pressure is lowered, so it may amplify rather than initiate the disease via a positive feedback loop. There is even emerging argument that CSF overproduction is unlikely to be the primary driver and that carbonic-anhydrase inhibition targets a consequence rather than the cause. Disentangling which node is initiating versus secondary across obese, non-obese, and atypical patients is the central unresolved question and would reorder the entire pathophysiology causal graph and its therapeutic targets.
Proposed experiments
Interventional perturbation cohort to order metabolic, venous, and CSF mechanisms
prospective interventional mechanistic cohort study Relation: this experiment is of type this experiment type This experiment is of type prospective interventional mechanistic cohort study.
exp_iih_mechanism_perturbation_ordering
Enroll newly diagnosed IIH patients (obese and non-obese strata) and apply mechanism-specific perturbations with simultaneous multi-axis monitoring.
Readouts
Metabolic-hormonal response and intracranial pressure
pathophysiology#Metabolic risk background
Quantify circulating metabolic and hormonal markers and body composition alongside intracranial pressure during a metabolic-hormonal intervention.
serum hormone quantification Relation: this readout is measured by this assay This readout is measured by serum hormone quantification. lumbar puncture opening pressure measurement Relation: this readout is measured by this assay This readout is measured by lumbar puncture opening pressure measurement.
Direction: NEGATIVE
CSF secretion response to carbonic anhydrase inhibition
pathophysiology#Choroid plexus CSF hypersecretion
Measure intracranial pressure and CSF dynamics before and after carbonic anhydrase inhibition.
cerebrospinal fluid dynamics assessment Relation: this readout is measured by this assay This readout is measured by cerebrospinal fluid dynamics assessment.
Direction: NEGATIVE
Trans-stenosis gradient and pressure coupling
pathophysiology#Venous sinus stenosis
Measure the transverse-sinus trans-stenosis pressure gradient before and after intracranial pressure is lowered, and before and after stenting.
catheter cerebral venography pressure gradient measurement Relation: this readout is measured by this assay This readout is measured by catheter cerebral venography pressure gradient measurement.
Direction: POSITIVE
Decision criterion
A pathway is supported as a modifiable mediator if its perturbation reproducibly changes the expected direct readout and ICP after accounting for weight loss, venous pressure, and outflow compensation. Improvement alone does not identify the initiating lesion; causal ordering additionally requires temporally resolved measurements before disease onset or a justified causal mediation design.
Would support
pathophysiology#Metabolic risk background pathophysiology#Choroid plexus CSF hypersecretion pathophysiology#Venous sinus stenosis
Show evidence (2 references)
PMID:33631966 SUPPORT Other
"Several mechanisms have been proposed as the underlying cause of IIH, such as an overproduction of cerebrospinal fluid (CSF), outflow obstruction, elevated pressure in the venous sinuses and more recently a dysfunction in the glymphatic pathway as well as hormonal alterations."
Directly enumerates the competing candidate mechanisms whose causal ordering is unresolved.
PMID:26700907 SUPPORT Other
"Pathogenesis has not been fully elucidated, but several causal factors have been proposed."
Confirms that the pathogenesis and causal ordering of the proposed factors remain unestablished.
Do the distinct secretory and drainage changes in rodent models occur in the same human IIH subgroups?
HUMAN MODEL MISMATCH OPEN gap_iih_secretory_transport_and_outflow_translation
Attached to
pathophysiology#Choroid plexus CSF hypersecretion pathophysiology#Impaired cerebrospinal fluid outflow
Rodent findings differ by strain, diet, hormonal perturbation, and assay: one high-fat paradigm increases secretion, another increases outflow resistance, and obese Zucker rats compensate for testosterone-induced secretion. Human androgen excess and drug-induced ICP reduction are insufficient to resolve the dominant human pathway. MRI water exchange and aqueductal flow must be validated against net secretion before being treated as direct production measurements.
Show evidence (3 references)
PMID:37328884 SUPPORT Model Organism
"HFD-fed rats presented with increased ICP (65%), which was accompanied by increased CSF outflow resistance (50%) without altered CSF secretion rate or choroid plexus gene expression."
High-fat feeding elevates ICP through drainage resistance in this rat paradigm, providing an alternative to obligatory hypersecretion.
PMID:38273331 SUPPORT Model Organism
"Adjuvant testosterone treatment of obese rats elevated the CSF secretion rate, although with no effect on the ICP, due to elevated CSF drainage capacity of these rats."
Compensatory drainage prevents ICP elevation despite higher secretion, showing that secretion is not sufficient in every model.
PMID:41279197 SUPPORT Model Organism
"Using high-resolution 3D balanced steady-state free precession MRI in rats, we demonstrate robust and spatially widespread D2O-induced CSF signal loss that is selectively suppressed by acetazolamide, a carbonic anhydrase inhibitor known to suppress CSF production by the choroid plexus."
Shows what the validation this gap demands looks like: a noninvasive production readout anchored to pharmacological suppression of secretion rather than assumed from water exchange. It is a rat study and a preprint that has not been peer reviewed, so it makes the human measurement a translation problem rather than an unsolved methodological one, and it does not itself measure anything in IIH.
Which genetic susceptibility findings replicate in larger, independently phenotyped IIH cohorts?
KNOWLEDGE GAP OPEN gap_iih_genetic_susceptibility
Attached to
disease#pseudotumor cerebri
The earlier NORDIC IIHTT GWAS and later small familial haplotype study generate candidates but do not establish a Mendelian IIH gene or a genome-wide significant causal locus. The familial study’s P<0.01 exploratory threshold and relatedness/age imbalance require replication. Its CA5A candidate cannot be treated as proof that mitochondrial carbonic anhydrase drives choroid plexus secretion.
Show evidence (2 references)
PMID:29608535 SUPPORT Human Clinical
"The study was limited by its modest size and thus would have only been able to demonstrate highly significant association on a genome-wide scale for relatively common alleles exerting large effects."
The first rigorous IIHTT GWAS identifies a power limitation, not a definitive causal gene.
PMID:38528581 SUPPORT Human Clinical
"Samples from 22 female participants (11 patients and 11 controls) were evaluated for haplotype clustering and genome-wide association studies (GWAS)."
Defines the actual small analyzed cohort rather than conflating it with all recruited subjects.
⚙

Pathophysiology

13
Dysregulated cerebrospinal fluid dynamics
An imbalance between cerebrospinal fluid production and effective outflow contributes to the raised-pressure state. This is a system-level state encompassing distinct secretory and drainage mechanisms, whose relative contributions in human IIH remain unresolved.
Downstream
Elevated intracranial pressure An imbalance in fluid production and effective outflow can raise ICP; the pressure response depends on venous pressure and compliance.
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"The pathophysiology involves dysregulation of cerebrospinal fluid (CSF) dynamics and venous sinus pressure"
This directly supports dysregulated CSF dynamics as the core mechanism.
Elevated intracranial pressure
Persistently elevated intracranial pressure causes the characteristic neuro-ophthalmologic and headache syndrome of pseudotumor cerebri.
Animal models
Testosterone-treated obese female Zucker rat Rattus norvegicus fails to recapitulate
Downstream
Optic nerve axoplasmic transport impairment Raised pressure is transmitted into the optic nerve sheath and impedes axonal transport.
Headache syndrome Raised pressure contributes to headache, although headache burden may persist independently of mean ICP.
Venous sinus stenosis Raised intracranial pressure can compress the transverse sinuses, worsening venous sinus stenosis and closing a positive feedback loop.
Diplopia Pressure-associated sixth nerve dysfunction can cause horizontal diplopia; the precise stretch/compression mechanism is not fully established.
Hyposmia Lowering ICP by lumbar puncture improves olfactory testing in a small IIH cohort. Peri-olfactory CSF pressure is a proposed intermediate; its precise causal contribution remains uncertain.
Show evidence (1 reference)
PMID:38575259 SUPPORT Other
"Pseudotumor cerebri syndrome is a syndrome of increased cerebrospinal fluid pressure without ventriculomegaly, mass lesion, or meningeal abnormality."
This directly supports elevated CSF pressure as the defining proximal abnormality.
Metabolic risk background
IIH is strongly associated with obesity and female reproductive age. Human cohorts also show insulin and leptin resistance and altered adipose metabolism beyond simple obesity. These associations motivate hormonal and outflow hypotheses but do not identify one obligatory initiating pathway.
Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Downstream
Androgen excess A distinct androgen profile accompanies the metabolic phenotype of adult women with IIH; the causal coupling remains hypothetical. Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Altered glucocorticoid metabolism Elevated systemic and adipose 11β-HSD1 activity accompanies active IIH, but causal mediation is unresolved. Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Impaired cerebrospinal fluid outflow High-fat feeding can increase drainage resistance in rats; the corresponding human metabolic-to-outflow mechanism remains unconfirmed. Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Show evidence (2 references)
PMID:34929642 SUPPORT Other
"IIH demonstrates a strong predilection towards obese women of reproductive age"
This supports the major metabolic-epidemiologic background on which IIH develops.
PMID:33848268 SUPPORT Human Clinical
"We demonstrate an insulin- and leptin-resistant phenotype in IIH in excess of that driven by obesity."
Matched human observations support metabolic dysregulation beyond obesity alone.
Choroid plexus CSF hypersecretion
Mechanism confidence: Provisional
Increased secretory transport at the choroid plexus is a candidate contributor to raised ICP. Human androgen profiles and testosterone perturbations of rodent choroid plexus support this arm, with Na+/K+-ATPase activation reported in cultured cells and NKCC1 activation in chronically treated rats. Direct demonstration that excess secretion initiates human IIH is lacking. GLP-1 receptor agonism inhibits secretory transport experimentally and lowers human ICP; this therapeutic effect does not establish endogenous GLP-1 deficiency or prove hypersecretion is primary.
Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
choroid plexus epithelial cell CL:0000706 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves choroid plexus epithelial cell (CL:0000706). CL:0000706 is a cell type from the Cell Ontology.
choroid plexus CSF hypersecretion GO:0033326 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased choroid plexus CSF hypersecretion, annotated with cerebrospinal fluid secretion (GO:0033326). GO:0033326 is a biological process from the Gene Ontology. ↑ INCREASED
choroid plexus Na+/K+-ATPase activity GO:0005391 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased choroid plexus Na+/K+-ATPase activity, annotated with P-type sodium:potassium-exchanging transporter activity (GO:0005391). GO:0005391 is a molecular function from the Gene Ontology. ↑ INCREASED choroid plexus NKCC1 cotransporter activity GO:0008511 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased choroid plexus NKCC1 cotransporter activity, annotated with sodium:potassium:chloride symporter activity (GO:0008511). GO:0008511 is a molecular function from the Gene Ontology. ↑ INCREASED
Animal models
Testosterone-treated female Wistar rat Rattus norvegicus partially recapitulates
Downstream
Dysregulated cerebrospinal fluid dynamics Higher secretion can shift fluid balance when outflow compensation is insufficient. Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Show evidence (2 references)
PMID:37328884 SUPPORT Model Organism
"Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%) and CSF secretion rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter, NKCC1."
Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated mechanism; human IIH secretion was not measured.
PMID:30753168 SUPPORT In Vitro
"We show that in a rat choroid plexus cell line, testosterone significantly enhanced the activity of Na+/K+-ATPase, a surrogate of CSF secretion."
The cell-line result measures a secretion surrogate, whereas the separate chronic-rat experiment implicates NKCC1.
Venous sinus stenosis
Transverse-sigmoid sinus narrowing can reflect an intrinsic luminal lesion or extrinsic pressure-dependent compression. The relative distribution in stenting cohorts cannot be generalized to all IIH. Persistence of intrinsic narrowing after ICP normalization supports an anatomic contributor but does not by itself establish the initiating event.
Primary Venous Sinus Obstruction Model
Downstream
Intracranial venous hypertension A hemodynamically significant narrowing raises upstream venous pressure through a trans-stenotic gradient. Primary Venous Sinus Obstruction Model
Pulsatile tinnitus Abnormal venous flow is a proposed source of pulse-synchronous sound; the auditory mechanism is inferred and is not proven in every patient.
Show evidence (2 references)
PMID:37410913 SUPPORT Other
"Venous sinus stenosis, typically at the junction of the transverse and sigmoid sinus, is increasingly recognized as a contributor to the pathophysiology of idiopathic intracranial hypertension (IIH), whether it be the intrinsic type that does not reverse with normalization of intracranial..."
Intrinsic and pressure-responsive extrinsic lesions are distinct morphologies; persistence alone does not prove that the lesion preceded IIH.
PMID:30219791 SUPPORT Human Clinical
"Stenosis was extrinsic in 63% (n=44) and intrinsic in 37% (n=26) of patients."
Supplies the cohort figures behind this node's distribution statement: in 70 consecutive patients stented at one center, just over a third had intrinsic narrowing. The proportion is incidental to that study's own question about vein of Labbé drainage and comes from a selected stented series, so it bounds the size of the intrinsic subgroup in such cohorts rather than in IIH generally.
Optic nerve axoplasmic transport impairment
Raised intracranial pressure is transmitted to the perioptic subarachnoid space and impairs axoplasmic transport in retinal ganglion cell axons at the optic nerve head.
retinal ganglion cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal ganglion cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology.
optic nerve axonal transport GO:0098930 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased optic nerve axonal transport, annotated with axonal transport (GO:0098930). GO:0098930 is a biological process from the Gene Ontology. ↓ DECREASED
optic nerve UBERON:0000941 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in optic nerve, annotated with cranial nerve II (UBERON:0000941). UBERON:0000941 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Papilledema Pressure-induced axoplasmic stasis produces optic disc edema.
Optic nerve axonal injury Persistent transport impairment can compromise axonal perfusion and damage the optic nerve.
Transient visual obscurations Transient optic nerve head dysfunction can interrupt vision reversibly; this differs from permanent axonal injury.
Visual field defect Optic disc and nerve dysfunction cause detectable field defects before severe central acuity loss.
Show evidence (1 reference)
PMID:34813854 SUPPORT Other
"Papilledema is caused by transmission of elevated ICP to the subarachnoid space surrounding the optic nerve that hinders axoplasmic transport within ganglion cell axons."
This review supports the pressure-transmission and axoplasmic-transport mechanism linking raised intracranial pressure to optic nerve head edema.
CGRP-mediated trigeminovascular headache signaling
Mechanism confidence: Provisional
CGRP provocation triggers typical migraine-like IIH headache without increasing mean ICP in a small randomized crossover study of women with IIH and no prior migraine. The observed rise in ICP pulse amplitude was an exploratory endpoint in a small subset without adjustment for multiple testing. These results support a trigeminovascular pain component but do not demonstrate that raised pressure initiates endogenous CGRP release.
trigeminal nociceptor CL:0000198 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves trigeminal nociceptor, annotated with pain receptor cell (CL:0000198). CL:0000198 is a cell type from the Cell Ontology.
trigeminovascular pain signaling GO:0019233 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased trigeminovascular pain signaling, annotated with sensory perception of pain (GO:0019233). GO:0019233 is a biological process from the Gene Ontology. ↑ INCREASED CGRP-mediated neuropeptide signaling GO:0007218 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal CGRP-mediated neuropeptide signaling, annotated with neuropeptide signaling pathway (GO:0007218). GO:0007218 is a biological process from the Gene Ontology. ⚠ ABNORMAL
dura mater UBERON:0002363 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in dura mater (UBERON:0002363). UBERON:0002363 is an anatomical location from the Uberon multi-species anatomy ontology. trigeminal ganglion UBERON:0001675 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in trigeminal ganglion (UBERON:0001675). UBERON:0001675 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Headache syndrome CGRP/neuropeptide activation of trigeminovascular pain pathways produces the migraine-like headache attacks that dominate IIH morbidity.
Show evidence (2 references)
PMID:41989095 SUPPORT Human Clinical
"CGRP reliably provoked typical IIH headache attacks (which have migraine-like features) and increased ICP pulse amplitude, as a measure of intracranial compliance, without altering mean pressure."
Randomized crossover provocation data support CGRP-dependent trigeminovascular signaling and altered pressure compliance as a mechanism for IIH headache attacks.
PMID:41989095 SUPPORT Human Clinical
"These findings provide mechanistic support for CGRP involvement in headache attributed to IIH and justify prospective evaluation of CGRP pathway blockade in this population."
The authors explicitly interpret the trial as mechanistic support for CGRP involvement in IIH-attributed headache.
Headache syndrome
Headache is the predominant symptomatic morbidity of pseudotumor cerebri. It reflects the elevated-pressure state, but current human provocation data support an additional CGRP-mediated trigeminovascular component that can vary independently of mean intracranial pressure.
Downstream
Headache The pain pathway manifests as the clinical headache phenotype.
Show evidence (1 reference)
PMID:35103000 SUPPORT Other
"headache is the predominant morbidity in over 90%."
This directly supports headache as the dominant symptomatic output of the pressure syndrome.
Androgen excess
Mechanism confidence: Provisional
Women with active IIH show increased serum and CSF testosterone and increased CSF androstenedione compared with matched controls. This is a measured hormonal association; secretion-promoting effects come from rodent experiments.
Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Downstream
Choroid plexus CSF hypersecretion Testosterone can enhance choroid plexus transport and secretion in rodent models; extrapolation to human IIH remains emerging. Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Show evidence (1 reference)
PMID:30753168 SUPPORT Human Clinical
"Women with IIH showed a pattern of androgen excess distinct to that observed in PCOS and simple obesity, with increased serum testosterone and increased CSF testosterone and androstenedione."
Human steroid profiling demonstrates an association in adult women; it does not establish that androgen excess initiates raised pressure.
Altered glucocorticoid metabolism
Mechanism confidence: Provisional
Systemic and adipose 11β-HSD1 activity is elevated in active IIH and decreases with weight loss. Its contribution to local choroid plexus or arachnoid granulation function remains unresolved, and AZD4017 did not establish benefit on the primary randomized ICP endpoint.
Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Downstream
Dysregulated cerebrospinal fluid dynamics Glucocorticoid metabolism is proposed to influence secretion and/or drainage structures; association and target engagement do not establish mediation. Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
Show evidence (2 references)
PMID:35584002 SUPPORT Human Clinical
"Compared to control subjects, patients with active IIH had increased systemic 11β-hydroxysteroid dehydrogenase (11β-HSD1) and 5α-reductase activity."
The metabolic phenotype is observed in matched human cohorts, without establishing a choroid plexus-specific initiating mechanism.
PMID:32954315 SUPPORT Human Clinical
"At 12 weeks, lumbar puncture pressure was lower in the AZD4017 group (29.7 cmH2O) compared with placebo (31.3 cmH2O), but the difference between groups was not statistically significant (mean difference: -2.8, 95% confidence interval: -7.1 to 1.5; P = 0.2)."
The primary between-group endpoint did not establish efficacy; exploratory within-group changes and biomarker correlations cannot substitute for that comparison.
Intracranial venous hypertension
Elevated dural sinus pressure reduces the driving gradient for CSF outflow into the venous circulation and contributes to raised intracranial pressure.
Primary Venous Sinus Obstruction Model
Downstream
Impaired cerebrospinal fluid outflow Elevated venous back-pressure reduces the pressure gradient available for CSF absorption. Primary Venous Sinus Obstruction Model
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"The pathophysiology involves dysregulation of cerebrospinal fluid (CSF) dynamics and venous sinus pressure"
This directly supports dysregulated CSF dynamics as the core mechanism.
Impaired cerebrospinal fluid outflow
Mechanism confidence: Provisional
Reduced effective CSF drainage can disturb fluid balance independently of excess secretion. Increased venous pressure is one plausible contributor. High-fat-fed rats show an outflow-resistance phenotype in one experimental paradigm, whereas other rat studies report secretion changes; no single animal paradigm establishes the dominant human mechanism.
Primary Venous Sinus Obstruction Model
Animal models
High-fat-fed female Wistar rat Rattus norvegicus partially recapitulates
Downstream
Dysregulated cerebrospinal fluid dynamics Reduced outflow shifts CSF balance toward a raised-pressure state. Primary Venous Sinus Obstruction Model
Show evidence (1 reference)
PMID:37328884 SUPPORT Model Organism
"HFD-fed rats presented with increased ICP (65%), which was accompanied by increased CSF outflow resistance (50%) without altered CSF secretion rate or choroid plexus gene expression."
High-fat feeding elevates ICP through drainage resistance in this rat paradigm, providing an alternative to obligatory hypersecretion.
Optic nerve axonal injury
Prolonged papilledema-associated axoplasmic stasis and intraneuronal ischemia can cause irreversible retinal ganglion cell axon injury.
Downstream
Visual loss Optic nerve axonal injury impairs visual function and can make loss permanent.
Show evidence (1 reference)
PMID:28539794 SUPPORT Other
"Irrespective of the cause, visual loss is the feared morbidity of papilledema, and the main mechanism of optic nerve damage is intraneuronal ischemia secondary to axoplasmic flow stasis."
Persistent axoplasmic stasis can produce ischemic optic nerve injury and visual loss.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for pseudotumor cerebri Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Ear 1
Pulsatile tinnitus HP:0008629 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulsatile tinnitus (HP:0008629). HP:0008629 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"The primary symptoms include headache, vision loss, and pulsatile tinnitus"
This directly supports pulsatile tinnitus as a primary symptom.
Eye 5
Papilledema HP:0001085 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Papilledema (HP:0001085). HP:0001085 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure, manifested by papilledema"
This directly supports papilledema as a defining sign.
Visual loss HP:0000572 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual loss (HP:0000572). HP:0000572 is a phenotype from the Human Phenotype Ontology.
A general population frequency is not assigned. The IIHTT cohort required mild visual field loss at entry; its 32% self-reported visual-loss frequency is a symptom measure in a selected cohort, not the prevalence of objective visual impairment or permanent visual loss in all IIH.
Show evidence (2 references)
PMID:34929642 SUPPORT Other
"The primary symptoms include headache, vision loss, and pulsatile tinnitus"
This directly supports visual loss as a primary symptom.
PMID:24756302 SUPPORT Human Clinical
"Given that the IIHTT entry criteria required mild visual field loss in the worse (study) eye, our perimetric results are not representative of visual loss in IIH in general."
The study explicitly limits generalization of its selected visual-loss cohort; objective field defects and self-reported symptoms have different denominators.
Transient visual obscurations FREQUENT Visual loss HP:0000572 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Transient visual obscurations, annotated with Visual loss (HP:0000572), qualified as temporality transient. HP:0000572 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:24756302 SUPPORT Human Clinical
"Transient visual obscurations occurred in 68% of patients, back pain in 53%, and pulse synchronous tinnitus in 52%."
Baseline IIHTT symptom frequencies apply to the selected untreated cohort with mild visual field loss, not to all IIH.
Diplopia OCCASIONAL HP:0000651 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diplopia (HP:0000651). HP:0000651 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24756302 SUPPORT Human Clinical
"While binocular diplopia was reported in 18%, only 3% had an esotropia on examination, suggesting the presence of sixth nerve palsy; this is best explained by the diplopia likely being transient."
The IIHTT cohort distinguishes reported diplopia from a demonstrable examination deficit.
Visual field defect HP:0001123 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual field defect (HP:0001123). HP:0001123 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24756302 SUPPORT Human Clinical
"A partial arcuate visual field defect with an enlarged blind spot was the most common perimetric finding."
Supports characteristic visual field loss in the trial cohort.
Head and Neck 1
Hyposmia HP:0004409 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyposmia (HP:0004409). HP:0004409 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23794685 SUPPORT Human Clinical
"Our pilot study provides new evidence that olfaction is impaired in patients with IIH, especially in those who have been newly diagnosed or who have experienced a recent clinical deterioration."
Objective olfactory testing in 17 patients and matched controls supports hyposmia; the small study does not provide population prevalence.
Nervous System 2
Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"The primary symptoms include headache, vision loss, and pulsatile tinnitus"
This directly supports headache as a primary symptom.
Cognitive impairment HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24713214 SUPPORT Human Clinical
"Patients with IIH performed significantly worse than controls in four of six cognitive domains (p≤0.02)."
A prospective 31-patient case-control study found objective deficits, most pronounced in processing speed and reaction time. Controls were not matched for BMI, and deficits did not track ICP normalization, so a simple pressure-mediated mechanism is not asserted.
Constitutional 1
Back pain FREQUENT HP:0003418 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Back pain (HP:0003418). HP:0003418 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24756302 SUPPORT Human Clinical
"Transient visual obscurations occurred in 68% of patients, back pain in 53%, and pulse synchronous tinnitus in 52%."
Baseline IIHTT symptom frequencies apply to the selected untreated cohort with mild visual field loss, not to all IIH.
💊

Medical Actions

10
Acetazolamide
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: acetazolamide CHEBI:27690 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses acetazolamide (CHEBI:27690). CHEBI:27690 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Acetazolamide is the best-studied medical therapy and improves visual outcomes when combined with a weight-reduction program in patients with mild visual loss.
Mechanism Target:
INHIBITS Choroid plexus CSF hypersecretion — Carbonic anhydrase inhibition reduces CSF production; clinical visual benefit does not prove baseline hypersecretion is the initiating lesion.
Show evidence (1 reference)
PMID:24756514 SUPPORT INDIRECT Human Clinical
"In patients with IIH and mild visual loss, the use of acetazolamide with a low-sodium weight-reduction diet compared with diet alone resulted in modest improvement in visual field function."
This randomized trial directly supports acetazolamide as disease-relevant therapy.
Target Phenotypes: Papilledema HP:0001085 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Papilledema (HP:0001085). HP:0001085 is a phenotype from the Human Phenotype Ontology. Visual loss HP:0000572 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Visual loss (HP:0000572). HP:0000572 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24756514 SUPPORT Human Clinical
"In patients with IIH and mild visual loss, the use of acetazolamide with a low-sodium weight-reduction diet compared with diet alone resulted in modest improvement in visual field function."
This randomized trial directly supports acetazolamide as disease-relevant therapy.
Weight-reduction intervention
Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
Platform: Behavioral / lifestyle
Weight reduction is a core disease-directed intervention in overweight patients with IIH.
Mechanism Target:
MODULATES Metabolic risk background — Sustained weight reduction modifies the metabolic risk state associated with IIH.
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"The Idiopathic Intracranial Hypertension Treatment Trial, the first of its kind randomized controlled trial on IIH, provides class I evidence for treatment with weight loss and acetazolamide."
This directly supports weight loss as a disease-directed intervention.
Target Phenotypes: Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology. Papilledema HP:0001085 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Papilledema (HP:0001085). HP:0001085 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34929642 SUPPORT Other
"The Idiopathic Intracranial Hypertension Treatment Trial, the first of its kind randomized controlled trial on IIH, provides class I evidence for treatment with weight loss and acetazolamide."
This directly supports weight loss as a disease-directed intervention.
Exenatide
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: exenatide CHEBI:748790 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses exenatide (CHEBI:748790). CHEBI:748790 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Peptide
Investigational GLP-1 receptor agonist for IIH. A randomized trial recruited 16 women with active IIH and found rapid and sustained ICP reductions using a prespecified alpha of 0.1; the 12-week P value was 0.058. Larger trials are needed to establish clinical outcomes.
Mechanism Target:
INHIBITS Choroid plexus CSF hypersecretion — Preclinical GLP-1 receptor activation reduces secretory pump activity; the human trial measured ICP rather than secretion or choroid plexus target engagement.
Show evidence (1 reference)
PMID:28835515 SUPPORT In Vitro
"Acute treatment with exendin-4 reduced Na+- and K+-dependent adenosine triphosphatase activity, a key regulator of CSF secretion, in cell cultures."
GLP-1 receptor agonism suppresses the secretory transport apparatus in cultured cells; this is a therapeutic perturbation rather than evidence of deficient endogenous signaling in IIH.
Show evidence (1 reference)
PMID:36907221 SUPPORT Human Clinical
"Exenatide significantly and meaningfully lowered intracranial pressure at 2.5 h -5.7 ± 2.9 cmCSF (P = 0.048); 24 h -6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks -5.6 ± 3.0 cmCSF (P = 0.058)."
The small randomized trial supports ICP lowering; alpha was prespecified at 0.1 and direct CSF secretion was not measured.
AZD4017
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: AZD4017 Relation: this treatment uses this therapeutic agent This treatment uses AZD4017.
Platform: Small molecule
Investigational 11β-HSD1 inhibitor. The 31-participant randomized trial showed biochemical target engagement but did not establish ICP lowering on the primary between-group comparison; exploratory within-group changes do not establish clinical efficacy.
Mechanism Target:
INHIBITS Altered glucocorticoid metabolism — AZD4017 inhibits 11β-HSD1 in vivo, but the trial did not establish that this improves the primary ICP endpoint.
Show evidence (1 reference)
PMID:32954315 SUPPORT Human Clinical
"AZD4017 was safe and well tolerated and inhibited 11β-hydroxysteroid dehydrogenase type 1 activity in vivo."
Supports biochemical target engagement, not proven clinical efficacy.
Show evidence (1 reference)
PMID:32954315 SUPPORT Human Clinical
"At 12 weeks, lumbar puncture pressure was lower in the AZD4017 group (29.7 cmH2O) compared with placebo (31.3 cmH2O), but the difference between groups was not statistically significant (mean difference: -2.8, 95% confidence interval: -7.1 to 1.5; P = 0.2)."
The primary between-group endpoint did not establish efficacy; exploratory within-group changes and biomarker correlations cannot substitute for that comparison.
Bariatric surgery
Action: bariatric surgeryNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is bariatric surgery (NCIT:C84399). NCIT:C84399 is a clinical intervention from the NCI Thesaurus. Ontology label: Bariatric Surgery NCIT:C84399
Platform: Surgery
Disease-directed weight-loss intervention supported by the IIH:WT randomized trial in women with active IIH and BMI at least 35. ICP improvement persisted over two years; the trial does not distinguish secretion from drainage mediation.
Mechanism Target:
MODULATES Metabolic risk background — Sustained surgically induced weight loss modifies the obesity-associated metabolic state.
Show evidence (1 reference)
PMID:33900360 SUPPORT Human Clinical
"The continued improvement over the course of 2 years shows the impact of this intervention with regard to sustained disease remission."
Supports durable benefit without establishing a unique hormonal mediator.
Show evidence (1 reference)
PMID:33900360 SUPPORT Human Clinical
"In this randomized clinical trial, bariatric surgery was superior to a CWM intervention in lowering intracranial pressure."
The randomized IIH:WT trial supports sustained disease modification in the studied population.
CSF diversion surgery
Action: CSF diversion surgeryNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is CSF diversion surgery, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Surgery
Shunting diverts CSF to lower intracranial pressure when vision is threatened or medical treatment fails. Surgical selection and revision burden require specialist evaluation.
Mechanism Target:
MODULATES Elevated intracranial pressure — Shunting diverts CSF to lower intracranial pressure when vision is threatened or medical treatment fails. Surgical selection and revision burden require specialist evaluation.
Show evidence (1 reference)
PMID:10387332 SUPPORT Other
"Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS) may improve vision and prevent deterioration of vision in patients with PTC."
Supports vision-protecting surgical options; comparative superiority is not established by this review.
Show evidence (1 reference)
PMID:10387332 SUPPORT Other
"Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS) may improve vision and prevent deterioration of vision in patients with PTC."
Supports vision-protecting surgical options; comparative superiority is not established by this review.
Optic nerve sheath fenestration
Action: Optic nerve sheath fenestrationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Optic nerve sheath fenestration, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Surgery
Fenestration decompresses the perioptic CSF compartment to protect vision in selected cases. It is not an established treatment for headache alone and does not necessarily normalize global ICP.
Mechanism Target:
MODULATES Optic nerve axoplasmic transport impairment — Fenestration decompresses the perioptic CSF compartment to protect vision in selected cases. It is not an established treatment for headache alone and does not necessarily normalize global ICP.
Show evidence (1 reference)
PMID:10387332 SUPPORT Other
"Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS) may improve vision and prevent deterioration of vision in patients with PTC."
Supports vision-protecting surgical options; comparative superiority is not established by this review.
Show evidence (1 reference)
PMID:10387332 SUPPORT Other
"Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS) may improve vision and prevent deterioration of vision in patients with PTC."
Supports vision-protecting surgical options; comparative superiority is not established by this review.
Venous sinus stenting
Action: venous sinus stentingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is venous sinus stenting, annotated with Endovascular Stenting (NCIT:C157840). NCIT:C157840 is a clinical intervention from the NCI Thesaurus. Ontology label: Endovascular Stenting NCIT:C157840
Platform: Surgery
An option for selected medically refractory IIH with hemodynamically significant stenosis. Observational studies support pressure and visual improvement; thrombosis, hemorrhage, restenosis and retreatment are relevant limitations, and clinical response does not prove venous stenosis was the initiating lesion.
Mechanism Target:
MODULATES Venous sinus stenosis — Stenting expands the narrowed lumen and reduces the trans-stenotic pressure gradient.
Show evidence (1 reference)
PMID:37410913 SUPPORT Other
"A growing body of evidence supports the use of venous sinus stenting as a viable option for medically refractory IIH, especially when papilledema threatens visual function."
The evidence is largely nonrandomized and applies to selected patients with relevant venous stenosis.
Show evidence (1 reference)
PMID:37410913 SUPPORT Other
"A growing body of evidence supports the use of venous sinus stenting as a viable option for medically refractory IIH, especially when papilledema threatens visual function."
The evidence is largely nonrandomized and applies to selected patients with relevant venous stenosis.
Topiramate
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: topiramate CHEBI:63631 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses topiramate (CHEBI:63631). CHEBI:63631 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Used off label for IIH, particularly when migraine-like headache and weight management are relevant. Evidence includes a small open-label comparison with acetazolamide; potential visual benefit and weight loss do not establish superiority or a proven ICP effect in that study.
Mechanism Target:
INHIBITS Choroid plexus CSF hypersecretion — Carbonic anhydrase inhibition is a proposed secretion-reducing action; the open-label clinical study did not isolate the mechanism.
Show evidence (1 reference)
PMID:17922725 SUPPORT INDIRECT Human Clinical
"Weight reduction as well as the reduction of the CSF formation is the possible mechanism of action."
The source explicitly presents the mechanism as possible, not directly measured.
Show evidence (1 reference)
PMID:17922725 SUPPORT Human Clinical
"When the follow-up visual field grades were compared with the visual field grades at the beginning of the study in each group a statistically significant improvement was detected with both drugs."
A small open-label comparison supports potential benefit of topiramate and acetazolamide, without proving equivalence or superiority.
Erenumab for persistent headache in ocular remission
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: erenumab NCIT:C169958 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses erenumab (NCIT:C169958). NCIT:C169958 is a therapeutic agent from the NCI Thesaurus.
Platform: Monoclonal antibody
Investigated for persistent chronic headache after papilledema has resolved. The prospective open-label evidence supports headache reduction in this specific setting; it must not be interpreted as treatment of raised ICP or prevention of visual injury.
Mechanism Target:
INHIBITS CGRP-mediated trigeminovascular headache signaling — CGRP-receptor blockade targets the headache pathway; surveillance for recurrent papilledema remains necessary regardless of headache relief.
Show evidence (1 reference)
PMID:33316102 SUPPORT Human Clinical
"This study provides evidence for the effectiveness of erenumab to treat headaches in IIH patients with resolution of papilledema."
The 55-woman prospective open-label study supports symptomatic benefit in ocular remission, without establishing pressure lowering or visual protection.
Show evidence (1 reference)
PMID:33316102 SUPPORT Human Clinical
"This study provides evidence for the effectiveness of erenumab to treat headaches in IIH patients with resolution of papilledema."
The 55-woman prospective open-label study supports symptomatic benefit in ocular remission, without establishing pressure lowering or visual protection.
🔬

Diagnosis

3
Brain MRI and venography
Brain imaging excludes structural causes, and CT or MR venography excludes cerebral venous thrombosis. Empty sella, optic nerve sheath distension and sinus narrowing can support the assessment but are not independently diagnostic.
magnetic resonance imaging procedure NCIT:C16809 NCI Thesaurus (NCIT)
Results: Normal brain imaging without mass lesion supports IIH after exclusion of secondary causes.
Show evidence (1 reference)
PMID:30298346 SUPPORT Other
"Diagnostic brain imaging in IIH should always include a CT- or MR venography"
Supports venous imaging in addition to brain MRI; the surrounding recommendation specifies exclusion of venous thrombosis.
Lumbar puncture with opening pressure measurement
After appropriate imaging, lumbar puncture documents opening pressure and CSF composition. Adult pressure above 25 cm CSF supports IIH in the complete clinical context; pediatric thresholds and sedation require age-specific interpretation. A single borderline result is not independently diagnostic.
Results: Elevated opening pressure with normal CSF composition supports the diagnosis.
Show evidence (2 references)
PMID:12455560 SUPPORT Other
"The syndrome of increased intracranial pressure without hydrocephalus or mass lesion and with normal CSF composition"
This directly supports lumbar puncture-based confirmation of pressure elevation with normal CSF composition.
PMID:23966248 SUPPORT Other
"clarification of normal opening pressure in children, and features distinguishing the syndrome of intracranial hypertension without papilledema from intracranial hypertension with papilledema"
Revised criteria distinguish pediatric pressure interpretation and the rare presentation without papilledema.
Neuro-ophthalmic examination and formal perimetry
Confirm papilledema, distinguish pseudopapilledema, and document visual acuity, pupils, fundus appearance and formal visual fields. OCT helps monitor optic nerve head swelling, but central acuity alone can miss functionally relevant field loss.
Show evidence (1 reference)
PMID:24756302 SUPPORT Human Clinical
"Patients with IIH with mild visual loss have typical symptoms, may have mild acuity loss, and have visual field defects, with predominantly arcuate loss and enlarged blind spots that require formal perimetry for detection."
Supports formal perimetry rather than relying on acuity alone.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from pseudotumor cerebri:

Cerebral sinovenous thrombosis Not Yet Curated MONDO:0017993
Overlapping Features Venous sinus thrombosis can mimic IIH with papilledema and raised intracranial pressure and must be excluded on imaging.
Show evidence (1 reference)
PMID:30298346 SUPPORT Other
"Diagnostic brain imaging in IIH should always include a CT- or MR venography"
Supports venous imaging in addition to brain MRI; the surrounding recommendation specifies exclusion of venous thrombosis.
Brain neoplasm Not Yet Curated MONDO:0021211
Overlapping Features Intracranial mass lesions must be excluded before the diagnosis of pseudotumor cerebri is made.
Show evidence (1 reference)
PMID:12455560 SUPPORT Other
"The syndrome of increased intracranial pressure without hydrocephalus or mass lesion and with normal CSF composition, previously referred to as pseudotumor cerebri, is a diagnosis of exclusion now termed idiopathic intracranial hypertension (IIH)."
This directly supports exclusion of mass lesions such as brain neoplasms when diagnosing pseudotumor cerebri.
Secondary medication-associated intracranial hypertension
Overlapping Features An identifiable medication or other secondary cause changes the diagnosis from primary IIH to secondary pseudotumor cerebri syndrome. Medication review and investigation of atypical presentations are part of excluding secondary disease.
Show evidence (1 reference)
PMID:23966248 SUPPORT Other
"The pseudotumor cerebri syndrome (PTCS) may be primary (idiopathic intracranial hypertension) or arise from an identifiable secondary cause."
Supports the required primary-versus-secondary distinction.
🔬

Clinical Trials

5
NCT01003639 PHASE_III COMPLETED
Randomized placebo-controlled IIHTT trial testing acetazolamide plus low-sodium weight-reduction diet in patients with mild visual loss.
Target Phenotypes: Visual loss HP:0000572 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Visual loss (HP:0000572). HP:0000572 is a phenotype from the Human Phenotype Ontology. Papilledema HP:0001085 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Papilledema (HP:0001085). HP:0001085 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT01003639 SUPPORT Human Clinical
"This trial will study subjects who have mild visual loss from IIH to (1) establish convincing, evidence-based treatment strategies for IIH to restore and protect vision, (2) follow subjects up to 4 years to observe the long-term treatment outcomes and (3) determine the cause of IIH."
The registered IIHTT trial directly targeted visual outcomes in IIH.
NCT02124486 NOT_APPLICABLE UNKNOWN
IIH:WT randomized comparison of bariatric surgery versus community weight management in women with BMI at least 35. Primary and two-year results are published; the registry currently gives overall status UNKNOWN for the extended study.
Show evidence (2 references)
PMID:33900360 SUPPORT Human Clinical
"TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02124486."
Connects the published randomized bariatric trial to its registered identifier.
clinicaltrials:NCT02124486 SUPPORT Other
"Participants will then be followed up for five years, with the most important measurement being their brain pressure after one year of being in the trial."
The registry records the planned follow-up and study design. Published results supply the efficacy evidence; this protocol text is not a result.
NCT02017444 PHASE_II COMPLETED
Completed AZD4017 trial; the primary between-group ICP endpoint was not significant.
Show evidence (2 references)
PMID:28923789 SUPPORT Other
"IIH:DT is the first phase II double-blind randomized placebo-controlled trial assessing the efficacy and safety of the novel pharmacological intervention, AZD4017, for the treatment of IIH."
Identifies the AZD4017 phase II trial whose registration is NCT02017444.
clinicaltrials:NCT02017444 SUPPORT Other
"Eligible participants will be randomly assigned to AZD4017 or a placebo ('dummy' with no active drug) for 3 months with a follow up a month later."
The registry records the planned follow-up and study design. Published results supply the efficacy evidence; this protocol text is not a result.
ISRCTN12678718 PHASE_II COMPLETED
Completed IIH:Pressure exenatide randomized trial with telemetric ICP measurements; clinical findings remain preliminary.
Show evidence (1 reference)
ICTRP:ISRCTN12678718 SUPPORT Other
"Target sample size | 16"
The registry records the 16-participant exenatide trial.
NCT05347147 PHASE_III TERMINATED
IIH EVOLVE trial of sustained-release exenatide (Presendin). The registry reports termination after the sponsor judged continuation not viable; it does not supply confirmatory phase III efficacy. Registry status checked during the September 2026 review.
Show evidence (1 reference)
clinicaltrials:NCT05347147 SUPPORT Other
"This trial has been designed to evaluate the efficacy and safety of a new formulation of exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH."
The registry establishes the investigational phase III program, not a successful efficacy result.
🐁

Animal Models

3
High-fat-fed female Wistar rat
Twenty-one-week high-fat diet model with increased ICP and outflow resistance, without increased secretion in this paradigm.
Species
Rattus norvegicus
Publication
PMID:37328884
Pathograph links
Impaired cerebrospinal fluid outflow partially recapitulates fidelity: moderate observes: organism
Limitations: Diet-induced rat physiology does not establish the initiating lesion in human IIH; other high-fat paradigms yield different secretion results.
Readouts
CSF outflow resistance
Direction: INCREASED
Show evidence (1 reference)
PMID:37328884 SUPPORT Model Organism
"HFD-fed rats presented with increased ICP (65%), which was accompanied by increased CSF outflow resistance (50%) without altered CSF secretion rate or choroid plexus gene expression."
High-fat feeding elevates ICP through drainage resistance in this rat paradigm, providing an alternative to obligatory hypersecretion.
Show evidence (1 reference)
PMID:37328884 SUPPORT Model Organism
"HFD-fed rats presented with increased ICP (65%), which was accompanied by increased CSF outflow resistance (50%) without altered CSF secretion rate or choroid plexus gene expression."
High-fat feeding elevates ICP through drainage resistance in this rat paradigm, providing an alternative to obligatory hypersecretion.
Testosterone-treated female Wistar rat
Chronic adjuvant testosterone model with NKCC1-associated increased CSF secretion and ICP.
Species
Rattus norvegicus
Publication
PMID:37328884
Pathograph links
Choroid plexus CSF hypersecretion partially recapitulates fidelity: moderate observes: organism
Limitations: Exogenous testosterone and rodent CSF transport cannot establish endogenous human IIH causation.
Readouts
CSF secretion rate
Direction: INCREASED
Show evidence (1 reference)
PMID:37328884 SUPPORT Model Organism
"Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%) and CSF secretion rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter, NKCC1."
Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated mechanism; human IIH secretion was not measured.
Show evidence (1 reference)
PMID:37328884 SUPPORT Model Organism
"Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%) and CSF secretion rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter, NKCC1."
Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated mechanism; human IIH secretion was not measured.
Testosterone-treated obese female Zucker rat
A compensating model in which secretion rises but ICP does not, because drainage capacity also rises.
Species
Rattus norvegicus
Publication
PMID:38273331
Pathograph links
Elevated intracranial pressure fails to recapitulate fidelity: low observes: organism
Limitations: Enhanced drainage prevents the elevated-ICP phenotype despite testosterone-induced hypersecretion.
Readouts
Intracranial pressure
Direction: UNCHANGED
Show evidence (1 reference)
PMID:38273331 SUPPORT Model Organism
"Adjuvant testosterone treatment of obese rats elevated the CSF secretion rate, although with no effect on the ICP, due to elevated CSF drainage capacity of these rats."
Compensatory drainage prevents ICP elevation despite higher secretion, showing that secretion is not sufficient in every model.
Show evidence (1 reference)
PMID:38273331 SUPPORT Model Organism
"Adjuvant testosterone treatment of obese rats elevated the CSF secretion rate, although with no effect on the ICP, due to elevated CSF drainage capacity of these rats."
Compensatory drainage prevents ICP elevation despite higher secretion, showing that secretion is not sufficient in every model.
{ }

Source YAML

click to show 
name: pseudotumor cerebri
creation_date: '2026-04-13T04:00:00Z'
description: >-
  Pseudotumor cerebri syndrome is elevated intracranial pressure without a mass lesion,
  hydrocephalus,
  or abnormal CSF composition. This entry primarily models idiopathic intracranial
  hypertension (IIH),
  after secondary causes are excluded. Its mechanisms include altered CSF secretion
  and outflow and intracranial
  venous hypertension on a metabolic background strongly associated with obesity.
  Their causal ordering
  is unresolved and can differ between patients. Headache, papilledema, transient
  visual obscurations,
  visual field loss, and pulsatile tinnitus dominate the clinical presentation; persistent
  optic nerve
  injury can cause permanent visual loss.
category: Complex
parents:
- disease
- intracranial hypertension
disease_term:
  preferred_term: pseudotumor cerebri
  term:
    id: MONDO:0009468
    label: pseudotumor cerebri
synonyms:
- idiopathic intracranial hypertension
- IIH
pathophysiology:
- name: Dysregulated cerebrospinal fluid dynamics
  description: >-
    An imbalance between cerebrospinal fluid production and effective outflow contributes
    to the raised-pressure
    state. This is a system-level state encompassing distinct secretory and drainage
    mechanisms, whose
    relative contributions in human IIH remain unresolved.
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The pathophysiology involves dysregulation of cerebrospinal fluid (CSF) dynamics
      and venous sinus
      pressure
    explanation: This directly supports dysregulated CSF dynamics as the core mechanism.
  downstream:
  - target: Elevated intracranial pressure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      An imbalance in fluid production and effective outflow can raise ICP; the pressure
      response depends
      on venous pressure and compliance.
    evidence:
    - reference: PMID:34929642
      reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The pathophysiology involves dysregulation of cerebrospinal fluid (CSF) dynamics
        and venous sinus
        pressure
      explanation: This directly supports dysregulated CSF dynamics as the core mechanism.
  biological_scale: ORGANISM
- name: Elevated intracranial pressure
  description: >-
    Persistently elevated intracranial pressure causes the characteristic neuro-ophthalmologic
    and headache
    syndrome of pseudotumor cerebri.
  evidence:
  - reference: PMID:38575259
    reference_title: The Pseudotumor Cerebri Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Pseudotumor cerebri syndrome is a syndrome of increased cerebrospinal fluid
      pressure without ventriculomegaly,
      mass lesion, or meningeal abnormality.
    explanation: This directly supports elevated CSF pressure as the defining proximal abnormality.
  downstream:
  - target: Optic nerve axoplasmic transport impairment
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Raised pressure is transmitted into the optic nerve sheath and impedes axonal
      transport.
    evidence:
    - reference: PMID:34813854
      reference_title: 'Papilledema: A review of etiology, pathophysiology, diagnosis, and management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Papilledema is caused by transmission of elevated ICP to the subarachnoid
        space surrounding the
        optic nerve that hinders axoplasmic transport within ganglion cell axons.
      explanation: >-
        This review supports the pressure-transmission and axoplasmic-transport mechanism
        linking raised
        intracranial pressure to optic nerve head edema.
  - target: Headache syndrome
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Raised pressure contributes to headache, although headache burden may persist
      independently of mean
      ICP.
    evidence:
    - reference: PMID:35103000
      reference_title: Idiopathic Intracranial Hypertension - Challenges and Pearls.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        headache is the predominant morbidity in over 90%.
      explanation: This directly supports headache as the dominant symptomatic output of the pressure syndrome.
  - target: Venous sinus stenosis
    description: >-
      Raised intracranial pressure can compress the transverse sinuses, worsening
      venous sinus stenosis
      and closing a positive feedback loop.
    evidence:
    - reference: PMID:28841117
      reference_title: Transient resolution of venous sinus stenosis after high-volume lumbar puncture in a patient with idiopathic intracranial hypertension.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This report suggests that TS and SS stenosis may be a downstream effect of
        elevated intracranial
        pressure in IIH, rather than its principal etiological mechanism.
      explanation: Supports a feedback edge in which raised intracranial pressure worsens venous sinus stenosis.
  - target: Diplopia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Pressure-associated sixth nerve dysfunction can cause horizontal diplopia; the
      precise stretch/compression
      mechanism is not fully established.
    evidence:
    - reference: PMID:30298346
      reference_title: European headache federation guideline on idiopathic intracranial hypertension.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Unilateral or bilateral sixth-nerve palsy may occur in IIH causing horizontal
        diplopia
      explanation: >-
        The guideline supports the cranial nerve pathway to diplopia.
  - target: Hyposmia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Lowering ICP by lumbar puncture improves olfactory testing in a small IIH cohort. Peri-olfactory
      CSF pressure is a proposed intermediate; its precise causal contribution remains uncertain.
    evidence:
    - reference: PMID:32088969
      reference_title: 'Lumbar puncture rapidly improves olfaction in patients with idiopathic intracranial hypertension: A cohort study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Lowering of increased intracranial pressure improves hyposmia.
      explanation: >-
        The 14-patient intervention cohort supports pressure-responsive olfactory impairment, although
        drainage is not a selective test of one olfactory mechanism.
- name: Metabolic risk background
  description: >-
    IIH is strongly associated with obesity and female reproductive age. Human cohorts
    also show insulin
    and leptin resistance and altered adipose metabolism beyond simple obesity. These
    associations motivate
    hormonal and outflow hypotheses but do not identify one obligatory initiating
    pathway.
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      IIH demonstrates a strong predilection towards obese women of reproductive age
    explanation: This supports the major metabolic-epidemiologic background on which IIH develops.
  - reference: PMID:33848268
    reference_title: Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrate an insulin- and leptin-resistant phenotype in IIH in excess of
      that driven by obesity.
    explanation: >-
      Matched human observations support metabolic dysregulation beyond obesity alone.
  downstream:
  - target: Androgen excess
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A distinct androgen profile accompanies the metabolic phenotype of adult women
      with IIH; the causal
      coupling remains hypothetical.
    evidence:
    - reference: PMID:30753168
      reference_title: A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Women with IIH showed a pattern of androgen excess distinct to that observed
        in PCOS and simple
        obesity, with increased serum testosterone and increased CSF testosterone
        and androstenedione.
      explanation: >-
        Human steroid profiling demonstrates an association in adult women; it does
        not establish that
        androgen excess initiates raised pressure.
    hypothesis_groups:
    - choroid_plexus_csf_hypersecretion
  - target: Altered glucocorticoid metabolism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Elevated systemic and adipose 11β-HSD1 activity accompanies active IIH, but
      causal mediation is
      unresolved.
    evidence:
    - reference: PMID:35584002
      reference_title: Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Compared to control subjects, patients with active IIH had increased systemic
        11β-hydroxysteroid
        dehydrogenase (11β-HSD1) and 5α-reductase activity.
      explanation: >-
        The metabolic phenotype is observed in matched human cohorts, without establishing
        a choroid plexus-specific
        initiating mechanism.
    hypothesis_groups:
    - choroid_plexus_csf_hypersecretion
  - target: Impaired cerebrospinal fluid outflow
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      High-fat feeding can increase drainage resistance in rats; the corresponding
      human metabolic-to-outflow
      mechanism remains unconfirmed.
    evidence:
    - reference: PMID:37328884
      reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        HFD-fed rats presented with increased ICP (65%), which was accompanied by
        increased CSF outflow
        resistance (50%) without altered CSF secretion rate or choroid plexus gene
        expression.
      explanation: >-
        High-fat feeding elevates ICP through drainage resistance in this rat paradigm,
        providing an alternative
        to obligatory hypersecretion.
    hypothesis_groups:
    - choroid_plexus_csf_hypersecretion
- name: Choroid plexus CSF hypersecretion
  mechanism_confidence: PROVISIONAL
  description: >-
    Increased secretory transport at the choroid plexus is a candidate contributor
    to raised ICP. Human
    androgen profiles and testosterone perturbations of rodent choroid plexus support
    this arm, with Na+/K+-ATPase
    activation reported in cultured cells and NKCC1 activation in chronically treated
    rats. Direct demonstration
    that excess secretion initiates human IIH is lacking. GLP-1 receptor agonism inhibits
    secretory transport
    experimentally and lowers human ICP; this therapeutic effect does not establish
    endogenous GLP-1 deficiency
    or prove hypersecretion is primary.
  cell_types:
  - preferred_term: choroid plexus epithelial cell
    term:
      id: CL:0000706
      label: choroid plexus epithelial cell
  biological_processes:
  - preferred_term: choroid plexus CSF hypersecretion
    modifier: INCREASED
    term:
      id: GO:0033326
      label: cerebrospinal fluid secretion
  molecular_functions:
  - preferred_term: choroid plexus Na+/K+-ATPase activity
    modifier: INCREASED
    term:
      id: GO:0005391
      label: P-type sodium:potassium-exchanging transporter activity
  - preferred_term: choroid plexus NKCC1 cotransporter activity
    modifier: INCREASED
    term:
      id: GO:0008511
      label: sodium:potassium:chloride symporter activity
  evidence:
  - reference: PMID:37328884
    reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%)
      and CSF secretion
      rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter,
      NKCC1.
    explanation: >-
      Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated
      mechanism;
      human IIH secretion was not measured.
  - reference: PMID:30753168
    reference_title: A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We show that in a rat choroid plexus cell line, testosterone significantly enhanced
      the activity
      of Na+/K+-ATPase, a surrogate of CSF secretion.
    explanation: >-
      The cell-line result measures a secretion surrogate, whereas the separate chronic-rat
      experiment
      implicates NKCC1.
  downstream:
  - target: Dysregulated cerebrospinal fluid dynamics
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Higher secretion can shift fluid balance when outflow compensation is insufficient.
    evidence:
    - reference: PMID:37328884
      reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%)
        and CSF secretion
        rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter,
        NKCC1.
      explanation: >-
        Chronic testosterone increases secretion and ICP in female rats through an
        NKCC1-associated mechanism;
        human IIH secretion was not measured.
    hypothesis_groups:
    - choroid_plexus_csf_hypersecretion
- name: Venous sinus stenosis
  description: >-
    Transverse-sigmoid sinus narrowing can reflect an intrinsic luminal lesion or
    extrinsic pressure-dependent
    compression. The relative distribution in stenting cohorts cannot be generalized
    to all IIH. Persistence
    of intrinsic narrowing after ICP normalization supports an anatomic contributor
    but does not by itself
    establish the initiating event.
  evidence:
  - reference: PMID:37410913
    reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Venous sinus stenosis, typically at the junction of the transverse and sigmoid
      sinus, is increasingly
      recognized as a contributor to the pathophysiology of idiopathic intracranial
      hypertension (IIH),
      whether it be the intrinsic type that does not reverse with normalization of
      intracranial pressure
      or the extrinsic type, which does.
    explanation: >-
      Intrinsic and pressure-responsive extrinsic lesions are distinct morphologies;
      persistence alone
      does not prove that the lesion preceded IIH.
  - reference: PMID:30219791
    reference_title: Impaired drainage of vein of Labbé following venous sinus stenting for idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Stenosis was extrinsic in 63% (n=44) and intrinsic in 37% (n=26) of patients.
    explanation: >-
      Supplies the cohort figures behind this node's distribution statement: in 70
      consecutive patients
      stented at one center, just over a third had intrinsic narrowing. The proportion
      is incidental
      to that study's own question about vein of Labbé drainage and comes from a selected
      stented series,
      so it bounds the size of the intrinsic subgroup in such cohorts rather than in
      IIH generally.
  downstream:
  - target: Intracranial venous hypertension
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      A hemodynamically significant narrowing raises upstream venous pressure through
      a trans-stenotic
      gradient.
    evidence:
    - reference: PMID:37410913
      reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Venous sinus stenosis, typically at the junction of the transverse and sigmoid
        sinus, is increasingly
        recognized as a contributor to the pathophysiology of idiopathic intracranial
        hypertension (IIH),
        whether it be the intrinsic type that does not reverse with normalization
        of intracranial pressure
        or the extrinsic type, which does.
      explanation: >-
        Intrinsic and pressure-responsive extrinsic lesions are distinct morphologies;
        persistence alone
        does not prove that the lesion preceded IIH.
    hypothesis_groups:
    - primary_venous_sinus_obstruction
  - target: Pulsatile tinnitus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Abnormal venous flow is a proposed source of pulse-synchronous sound; the auditory
      mechanism is
      inferred and is not proven in every patient.
    evidence:
    - reference: PMID:37410913
      reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        pulsatile tinnitus resolved in 84.7% of 515
      explanation: >-
        Resolution after stenting supports an indirect venous contribution in selected
        treated patients.
      directness: INDIRECT
- name: Optic nerve axoplasmic transport impairment
  description: >-
    Raised intracranial pressure is transmitted to the perioptic subarachnoid space
    and impairs axoplasmic
    transport in retinal ganglion cell axons at the optic nerve head.
  cell_types:
  - preferred_term: retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: optic nerve axonal transport
    modifier: DECREASED
    term:
      id: GO:0098930
      label: axonal transport
  locations:
  - preferred_term: optic nerve
    term:
      id: UBERON:0000941
      label: cranial nerve II
  evidence:
  - reference: PMID:34813854
    reference_title: 'Papilledema: A review of etiology, pathophysiology, diagnosis, and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Papilledema is caused by transmission of elevated ICP to the subarachnoid space
      surrounding the
      optic nerve that hinders axoplasmic transport within ganglion cell axons.
    explanation: >-
      This review supports the pressure-transmission and axoplasmic-transport mechanism
      linking raised
      intracranial pressure to optic nerve head edema.
  downstream:
  - target: Papilledema
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Pressure-induced axoplasmic stasis produces optic disc edema.
    evidence:
    - reference: PMID:34813854
      reference_title: 'Papilledema: A review of etiology, pathophysiology, diagnosis, and management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Papilledema is caused by transmission of elevated ICP to the subarachnoid
        space surrounding the
        optic nerve that hinders axoplasmic transport within ganglion cell axons.
      explanation: >-
        This review supports the pressure-transmission and axoplasmic-transport mechanism
        linking raised
        intracranial pressure to optic nerve head edema.
  - target: Optic nerve axonal injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Persistent transport impairment can compromise axonal perfusion and damage the
      optic nerve.
    evidence:
    - reference: PMID:28539794
      reference_title: 'Papilledema: epidemiology, etiology, and clinical management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Irrespective of the cause, visual loss is the feared morbidity of papilledema,
        and the main mechanism
        of optic nerve damage is intraneuronal ischemia secondary to axoplasmic flow
        stasis.
      explanation: >-
        Persistent axoplasmic stasis can produce ischemic optic nerve injury and visual
        loss.
  - target: Transient visual obscurations
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Transient optic nerve head dysfunction can interrupt vision reversibly; this
      differs from permanent
      axonal injury.
    evidence:
    - reference: PMID:24756302
      reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Transient visual obscurations (TVOs) are transient episodes of visual loss
        that usually last less
        than 30 seconds, occur in 1 or both eyes, and are followed by full visual
        recovery.
      explanation: >-
        The clinical description supports reversible visual dysfunction; optic nerve
        head ischemia is
        the proposed intermediary.
  - target: Visual field defect
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Optic disc and nerve dysfunction cause detectable field defects before severe
      central acuity loss.
    evidence:
    - reference: PMID:24756302
      reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Patients with IIH with mild visual loss have typical symptoms, may have mild
        acuity loss, and
        have visual field defects, with predominantly arcuate loss and enlarged blind
        spots that require
        formal perimetry for detection.
      explanation: >-
        Supports the visual-field manifestation of the optic nerve pathway.
- name: CGRP-mediated trigeminovascular headache signaling
  mechanism_confidence: PROVISIONAL
  description: >-
    CGRP provocation triggers typical migraine-like IIH headache without increasing mean ICP in a small
    randomized crossover study of women with IIH and no prior migraine. The observed rise in ICP pulse
    amplitude was an exploratory endpoint in a small subset without adjustment for multiple testing. These
    results support a trigeminovascular pain component but do not demonstrate that raised pressure initiates
    endogenous CGRP release.
  cell_types:
  - preferred_term: trigeminal nociceptor
    term:
      id: CL:0000198
      label: pain receptor cell
  biological_processes:
  - preferred_term: trigeminovascular pain signaling
    modifier: INCREASED
    term:
      id: GO:0019233
      label: sensory perception of pain
  - preferred_term: CGRP-mediated neuropeptide signaling
    modifier: ABNORMAL
    term:
      id: GO:0007218
      label: neuropeptide signaling pathway
  locations:
  - preferred_term: dura mater
    term:
      id: UBERON:0002363
      label: dura mater
  - preferred_term: trigeminal ganglion
    term:
      id: UBERON:0001675
      label: trigeminal ganglion
  evidence:
  - reference: PMID:41989095
    reference_title: Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CGRP reliably provoked typical IIH headache attacks (which have migraine-like
      features) and increased
      ICP pulse amplitude, as a measure of intracranial compliance, without altering
      mean pressure.
    explanation: >-
      Randomized crossover provocation data support CGRP-dependent trigeminovascular
      signaling and altered
      pressure compliance as a mechanism for IIH headache attacks.
  - reference: PMID:41989095
    reference_title: Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings provide mechanistic support for CGRP involvement in headache
      attributed to IIH and
      justify prospective evaluation of CGRP pathway blockade in this population.
    explanation: >-
      The authors explicitly interpret the trial as mechanistic support for CGRP involvement
      in IIH-attributed
      headache.
  downstream:
  - target: Headache syndrome
    description: >-
      CGRP/neuropeptide activation of trigeminovascular pain pathways produces the
      migraine-like headache
      attacks that dominate IIH morbidity.
    evidence:
    - reference: PMID:41989095
      reference_title: Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Twelve (71%) participants developed a typical IIH headache attack with migraine-like features
        after CGRP compared with three (18%) after placebo (risk difference 53%; 95% CI, 26-79; P = 0.004).
      explanation: >-
        Randomized crossover provocation provides human experimental evidence that CGRP can trigger IIH
        headache. Participants had no prior migraine and included active disease and ocular remission.
- name: Headache syndrome
  description: >-
    Headache is the predominant symptomatic morbidity of pseudotumor cerebri. It reflects
    the elevated-pressure
    state, but current human provocation data support an additional CGRP-mediated
    trigeminovascular component
    that can vary independently of mean intracranial pressure.
  evidence:
  - reference: PMID:35103000
    reference_title: Idiopathic Intracranial Hypertension - Challenges and Pearls.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      headache is the predominant morbidity in over 90%.
    explanation: This directly supports headache as the dominant symptomatic output of the pressure syndrome.
  downstream:
  - target: Headache
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The pain pathway manifests as the clinical headache phenotype.
    evidence:
    - reference: PMID:35103000
      reference_title: Idiopathic Intracranial Hypertension - Challenges and Pearls.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        headache is the predominant morbidity in over 90%.
      explanation: This directly supports headache as the dominant symptomatic output of the pressure syndrome.
- name: Androgen excess
  mechanism_confidence: PROVISIONAL
  biological_scale: MOLECULAR
  description: >-
    Women with active IIH show increased serum and CSF testosterone and increased
    CSF androstenedione
    compared with matched controls. This is a measured hormonal association; secretion-promoting
    effects
    come from rodent experiments.
  evidence:
  - reference: PMID:30753168
    reference_title: A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Women with IIH showed a pattern of androgen excess distinct to that observed
      in PCOS and simple
      obesity, with increased serum testosterone and increased CSF testosterone and
      androstenedione.
    explanation: >-
      Human steroid profiling demonstrates an association in adult women; it does
      not establish that androgen
      excess initiates raised pressure.
  downstream:
  - target: Choroid plexus CSF hypersecretion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Testosterone can enhance choroid plexus transport and secretion in rodent models;
      extrapolation
      to human IIH remains emerging.
    evidence:
    - reference: PMID:37328884
      reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%)
        and CSF secretion
        rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter,
        NKCC1.
      explanation: >-
        Chronic testosterone increases secretion and ICP in female rats through an
        NKCC1-associated mechanism;
        human IIH secretion was not measured.
    hypothesis_groups:
    - choroid_plexus_csf_hypersecretion
- name: Altered glucocorticoid metabolism
  mechanism_confidence: PROVISIONAL
  biological_scale: MOLECULAR
  description: >-
    Systemic and adipose 11β-HSD1 activity is elevated in active IIH and decreases
    with weight loss. Its
    contribution to local choroid plexus or arachnoid granulation function remains
    unresolved, and AZD4017
    did not establish benefit on the primary randomized ICP endpoint.
  evidence:
  - reference: PMID:35584002
    reference_title: Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared to control subjects, patients with active IIH had increased systemic
      11β-hydroxysteroid
      dehydrogenase (11β-HSD1) and 5α-reductase activity.
    explanation: >-
      The metabolic phenotype is observed in matched human cohorts, without establishing
      a choroid plexus-specific
      initiating mechanism.
  - reference: PMID:32954315
    reference_title: '11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 12 weeks, lumbar puncture pressure was lower in the AZD4017 group (29.7 cmH2O)
      compared with
      placebo (31.3 cmH2O), but the difference between groups was not statistically
      significant (mean
      difference: -2.8, 95% confidence interval: -7.1 to 1.5; P = 0.2).
    explanation: >-
      The primary between-group endpoint did not establish efficacy; exploratory within-group
      changes
      and biomarker correlations cannot substitute for that comparison.
  downstream:
  - target: Dysregulated cerebrospinal fluid dynamics
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Glucocorticoid metabolism is proposed to influence secretion and/or drainage
      structures; association
      and target engagement do not establish mediation.
    evidence:
    - reference: PMID:20826586
      reference_title: 'Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation?'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        11β-HSD1 and key elements of the glucocorticoid signaling pathway were expressed
        in CP and AGT.
      explanation: >-
        Both secretory choroid plexus and drainage arachnoid granulation tissue express
        the pathway; functional
        effects in human IIH are not established.
    - reference: PMID:32036786
      reference_title: Cerebrospinal fluid dynamics modulation by diet and cytokines in rats.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Increased CSF secretion was seen in both groups following HC treatment (by 132% in controls and 114% in HF) but only in control rats following TNF-α treatment (137% increase).
      explanation: >-
        Hydrocortisone raises the CSF secretion rate measured directly by ventriculo-cisternal
        perfusion
        in rats, which is the secretory half of the influence this edge proposes. The
        steroid was applied
        exogenously rather than regenerated locally by 11β-HSD1, so the result establishes
        glucocorticoid
        sensitivity of secretion without testing the enzymatic route this node asserts.
    hypothesis_groups:
    - choroid_plexus_csf_hypersecretion
- name: Intracranial venous hypertension
  biological_scale: TISSUE
  description: >-
    Elevated dural sinus pressure reduces the driving gradient for CSF outflow into
    the venous circulation
    and contributes to raised intracranial pressure.
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The pathophysiology involves dysregulation of cerebrospinal fluid (CSF) dynamics
      and venous sinus
      pressure
    explanation: This directly supports dysregulated CSF dynamics as the core mechanism.
  downstream:
  - target: Impaired cerebrospinal fluid outflow
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Elevated venous back-pressure reduces the pressure gradient available for CSF
      absorption.
    evidence:
    - reference: PMID:37410913
      reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Venous sinus stenosis, typically at the junction of the transverse and sigmoid
        sinus, is increasingly
        recognized as a contributor to the pathophysiology of idiopathic intracranial
        hypertension (IIH),
        whether it be the intrinsic type that does not reverse with normalization
        of intracranial pressure
        or the extrinsic type, which does.
      explanation: >-
        Intrinsic and pressure-responsive extrinsic lesions are distinct morphologies;
        persistence alone
        does not prove that the lesion preceded IIH.
    hypothesis_groups:
    - primary_venous_sinus_obstruction
- name: Impaired cerebrospinal fluid outflow
  mechanism_confidence: PROVISIONAL
  biological_scale: TISSUE
  description: >-
    Reduced effective CSF drainage can disturb fluid balance independently of excess
    secretion. Increased
    venous pressure is one plausible contributor. High-fat-fed rats show an outflow-resistance
    phenotype
    in one experimental paradigm, whereas other rat studies report secretion changes;
    no single animal
    paradigm establishes the dominant human mechanism.
  evidence:
  - reference: PMID:37328884
    reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      HFD-fed rats presented with increased ICP (65%), which was accompanied by increased
      CSF outflow
      resistance (50%) without altered CSF secretion rate or choroid plexus gene expression.
    explanation: >-
      High-fat feeding elevates ICP through drainage resistance in this rat paradigm,
      providing an alternative
      to obligatory hypersecretion.
  downstream:
  - target: Dysregulated cerebrospinal fluid dynamics
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced outflow shifts CSF balance toward a raised-pressure state.
    evidence:
    - reference: PMID:37328884
      reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        HFD-fed rats presented with increased ICP (65%), which was accompanied by
        increased CSF outflow
        resistance (50%) without altered CSF secretion rate or choroid plexus gene
        expression.
      explanation: >-
        High-fat feeding elevates ICP through drainage resistance in this rat paradigm,
        providing an alternative
        to obligatory hypersecretion.
    hypothesis_groups:
    - primary_venous_sinus_obstruction
- name: Optic nerve axonal injury
  biological_scale: TISSUE
  description: >-
    Prolonged papilledema-associated axoplasmic stasis and intraneuronal ischemia
    can cause irreversible
    retinal ganglion cell axon injury.
  evidence:
  - reference: PMID:28539794
    reference_title: 'Papilledema: epidemiology, etiology, and clinical management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Irrespective of the cause, visual loss is the feared morbidity of papilledema,
      and the main mechanism
      of optic nerve damage is intraneuronal ischemia secondary to axoplasmic flow
      stasis.
    explanation: >-
      Persistent axoplasmic stasis can produce ischemic optic nerve injury and visual
      loss.
  downstream:
  - target: Visual loss
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Optic nerve axonal injury impairs visual function and can make loss permanent.
    evidence:
    - reference: PMID:28539794
      reference_title: 'Papilledema: epidemiology, etiology, and clinical management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Irrespective of the cause, visual loss is the feared morbidity of papilledema,
        and the main mechanism
        of optic nerve damage is intraneuronal ischemia secondary to axoplasmic flow
        stasis.
      explanation: >-
        Persistent axoplasmic stasis can produce ischemic optic nerve injury and visual
        loss.
phenotypes:
- name: Headache
  category: Neurologic
  description: >-
    Headache is the dominant symptomatic burden in pseudotumor cerebri.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The primary symptoms include headache, vision loss, and pulsatile tinnitus
    explanation: This directly supports headache as a primary symptom.
- name: Papilledema
  category: Ophthalmic
  diagnostic: true
  description: >-
    Papilledema is the hallmark neuro-ophthalmologic sign of raised intracranial pressure
    in IIH.
  phenotype_term:
    preferred_term: Papilledema
    term:
      id: HP:0001085
      label: Papilledema
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial
      pressure,
      manifested by papilledema
    explanation: This directly supports papilledema as a defining sign.
- name: Visual loss
  category: Ophthalmic
  description: >-
    Visual dysfunction and permanent visual loss can occur if elevated intracranial
    pressure is not controlled.
  notes: >-
    A general population frequency is not assigned. The IIHTT cohort required mild
    visual field loss at entry; its 32% self-reported visual-loss frequency is a
    symptom measure in a selected cohort, not the prevalence of objective visual
    impairment or permanent visual loss in all IIH.
  phenotype_term:
    preferred_term: Visual loss
    term:
      id: HP:0000572
      label: Visual loss
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The primary symptoms include headache, vision loss, and pulsatile tinnitus
    explanation: This directly supports visual loss as a primary symptom.
  - reference: PMID:24756302
    reference_title: "The idiopathic intracranial hypertension treatment trial: clinical profile at baseline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Given that the IIHTT entry criteria required mild visual field loss in the
      worse (study) eye, our perimetric results are not representative of visual
      loss in IIH in general.
    explanation: >-
      The study explicitly limits generalization of its selected visual-loss
      cohort; objective field defects and self-reported symptoms have different
      denominators.

- name: Pulsatile tinnitus
  category: Otolaryngologic
  description: >-
    Pulsatile tinnitus is a common pressure-related symptom in pseudotumor cerebri.
  phenotype_term:
    preferred_term: Pulsatile tinnitus
    term:
      id: HP:0008629
      label: Pulsatile tinnitus
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The primary symptoms include headache, vision loss, and pulsatile tinnitus
    explanation: This directly supports pulsatile tinnitus as a primary symptom.
- name: Transient visual obscurations
  description: >-
    Brief reversible episodes of unilateral or bilateral visual dimming, distinguished
    from permanent
    optic nerve injury.
  phenotype_term:
    preferred_term: Transient visual obscurations
    term:
      id: HP:0000572
      label: Visual loss
    temporality: TRANSIENT
  evidence:
  - reference: PMID:24756302
    reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Transient visual obscurations occurred in 68% of patients, back pain in 53%,
      and pulse synchronous
      tinnitus in 52%.
    explanation: >-
      Baseline IIHTT symptom frequencies apply to the selected untreated cohort with
      mild visual field
      loss, not to all IIH.
  frequency: FREQUENT
- name: Back pain
  description: >-
    Back pain was reported in 53% of the IIHTT mild-visual-loss cohort. Its exact
    mechanism is less well
    established than the optic nerve pathway.
  phenotype_term:
    preferred_term: Back pain
    term:
      id: HP:0003418
      label: Back pain
  evidence:
  - reference: PMID:24756302
    reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Transient visual obscurations occurred in 68% of patients, back pain in 53%,
      and pulse synchronous
      tinnitus in 52%.
    explanation: >-
      Baseline IIHTT symptom frequencies apply to the selected untreated cohort with
      mild visual field
      loss, not to all IIH.
  frequency: FREQUENT
- name: Diplopia
  description: >-
    Typically binocular horizontal diplopia, sometimes transient and associated with
    sixth nerve dysfunction.
  phenotype_term:
    preferred_term: Diplopia
    term:
      id: HP:0000651
      label: Diplopia
  evidence:
  - reference: PMID:24756302
    reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While binocular diplopia was reported in 18%, only 3% had an esotropia on examination,
      suggesting
      the presence of sixth nerve palsy; this is best explained by the diplopia likely
      being transient.
    explanation: >-
      The IIHTT cohort distinguishes reported diplopia from a demonstrable examination
      deficit.
  frequency: OCCASIONAL
- name: Visual field defect
  description: >-
    Arcuate field loss and enlarged blind spots can occur despite preserved central
    visual acuity; formal
    perimetry detects them.
  phenotype_term:
    preferred_term: Visual field defect
    term:
      id: HP:0001123
      label: Visual field defect
  evidence:
  - reference: PMID:24756302
    reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A partial arcuate visual field defect with an enlarged blind spot was the most
      common perimetric
      finding.
    explanation: >-
      Supports characteristic visual field loss in the trial cohort.
- name: Cognitive impairment
  description: >-
    Impaired processing speed, reaction time, attention and visuospatial memory have been documented with
    formal testing. Cognitive deficits may persist after ICP and headache improve; the mechanism and contribution
    of comorbidity remain unresolved.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:24713214
    reference_title: 'Cognitive function in idiopathic intracranial hypertension: a prospective case-control study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with IIH performed significantly worse than controls in four of six cognitive domains (p≤0.02).
    explanation: >-
      A prospective 31-patient case-control study found objective deficits, most pronounced in processing
      speed and reaction time. Controls were not matched for BMI, and deficits did not track ICP normalization,
      so a simple pressure-mediated mechanism is not asserted.
- name: Hyposmia
  description: >-
    Olfactory dysfunction has been observed in IIH but is not a validated diagnostic
    or monitoring marker.
  phenotype_term:
    preferred_term: Hyposmia
    term:
      id: HP:0004409
      label: Hyposmia
  evidence:
  - reference: PMID:23794685
    reference_title: Olfactory dysfunction in patients with idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our pilot study provides new evidence that olfaction is impaired in patients with IIH, especially
      in those who have been newly diagnosed or who have experienced a recent clinical deterioration.
    explanation: >-
      Objective olfactory testing in 17 patients and matched controls supports hyposmia; the small study
      does not provide population prevalence.
treatments:
- name: Acetazolamide
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acetazolamide
      term:
        id: CHEBI:27690
        label: acetazolamide
  description: >-
    Acetazolamide is the best-studied medical therapy and improves visual outcomes
    when combined with
    a weight-reduction program in patients with mild visual loss.
  target_phenotypes:
  - preferred_term: Papilledema
    term:
      id: HP:0001085
      label: Papilledema
  - preferred_term: Visual loss
    term:
      id: HP:0000572
      label: Visual loss
  evidence:
  - reference: PMID:24756514
    reference_title: 'Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients with IIH and mild visual loss, the use of acetazolamide with a low-sodium
      weight-reduction
      diet compared with diet alone resulted in modest improvement in visual field
      function.
    explanation: This randomized trial directly supports acetazolamide as disease-relevant therapy.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Choroid plexus CSF hypersecretion
    treatment_effect: INHIBITS
    description: >-
      Carbonic anhydrase inhibition reduces CSF production; clinical visual benefit
      does not prove baseline
      hypersecretion is the initiating lesion.
    evidence:
    - reference: PMID:24756514
      reference_title: 'Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In patients with IIH and mild visual loss, the use of acetazolamide with a
        low-sodium weight-reduction
        diet compared with diet alone resulted in modest improvement in visual field
        function.
      explanation: This randomized trial directly supports acetazolamide as disease-relevant therapy.
      directness: INDIRECT
- name: Weight-reduction intervention
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  description: >-
    Weight reduction is a core disease-directed intervention in overweight patients
    with IIH.
  target_phenotypes:
  - preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  - preferred_term: Papilledema
    term:
      id: HP:0001085
      label: Papilledema
  evidence:
  - reference: PMID:34929642
    reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The Idiopathic Intracranial Hypertension Treatment Trial, the first of its kind
      randomized controlled
      trial on IIH, provides class I evidence for treatment with weight loss and acetazolamide.
    explanation: This directly supports weight loss as a disease-directed intervention.
  target_mechanisms:
  - target: Metabolic risk background
    treatment_effect: MODULATES
    description: >-
      Sustained weight reduction modifies the metabolic risk state associated with
      IIH.
    evidence:
    - reference: PMID:34929642
      reference_title: 'Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The Idiopathic Intracranial Hypertension Treatment Trial, the first of its
        kind randomized controlled
        trial on IIH, provides class I evidence for treatment with weight loss and
        acetazolamide.
      explanation: This directly supports weight loss as a disease-directed intervention.
- name: Exenatide
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: exenatide
      term:
        id: CHEBI:748790
        label: exenatide
  description: >-
    Investigational GLP-1 receptor agonist for IIH. A randomized trial recruited 16
    women with active
    IIH and found rapid and sustained ICP reductions using a prespecified alpha of
    0.1; the 12-week P
    value was 0.058. Larger trials are needed to establish clinical outcomes.
  evidence:
  - reference: PMID:36907221
    reference_title: 'The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Exenatide significantly and meaningfully lowered intracranial pressure at 2.5
      h -5.7 ± 2.9 cmCSF
      (P = 0.048); 24 h -6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks -5.6 ± 3.0 cmCSF
      (P = 0.058).
    explanation: >-
      The small randomized trial supports ICP lowering; alpha was prespecified at
      0.1 and direct CSF secretion
      was not measured.
  target_mechanisms:
  - target: Choroid plexus CSF hypersecretion
    treatment_effect: INHIBITS
    description: >-
      Preclinical GLP-1 receptor activation reduces secretory pump activity; the human
      trial measured
      ICP rather than secretion or choroid plexus target engagement.
    evidence:
    - reference: PMID:28835515
      reference_title: A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Acute treatment with exendin-4 reduced Na+- and K+-dependent adenosine triphosphatase
        activity,
        a key regulator of CSF secretion, in cell cultures.
      explanation: >-
        GLP-1 receptor agonism suppresses the secretory transport apparatus in cultured
        cells; this is
        a therapeutic perturbation rather than evidence of deficient endogenous signaling
        in IIH.
- name: AZD4017
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: AZD4017
  description: >-
    Investigational 11β-HSD1 inhibitor. The 31-participant randomized trial showed
    biochemical target
    engagement but did not establish ICP lowering on the primary between-group comparison;
    exploratory
    within-group changes do not establish clinical efficacy.
  evidence:
  - reference: PMID:32954315
    reference_title: '11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 12 weeks, lumbar puncture pressure was lower in the AZD4017 group (29.7 cmH2O)
      compared with
      placebo (31.3 cmH2O), but the difference between groups was not statistically
      significant (mean
      difference: -2.8, 95% confidence interval: -7.1 to 1.5; P = 0.2).
    explanation: >-
      The primary between-group endpoint did not establish efficacy; exploratory within-group
      changes
      and biomarker correlations cannot substitute for that comparison.
  target_mechanisms:
  - target: Altered glucocorticoid metabolism
    treatment_effect: INHIBITS
    description: >-
      AZD4017 inhibits 11β-HSD1 in vivo, but the trial did not establish that this
      improves the primary
      ICP endpoint.
    evidence:
    - reference: PMID:32954315
      reference_title: '11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AZD4017 was safe and well tolerated and inhibited 11β-hydroxysteroid dehydrogenase
        type 1 activity
        in vivo.
      explanation: >-
        Supports biochemical target engagement, not proven clinical efficacy.
- name: Bariatric surgery
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: bariatric surgery
    term:
      id: NCIT:C84399
      label: Bariatric Surgery
  description: >-
    Disease-directed weight-loss intervention supported by the IIH:WT randomized trial
    in women with active
    IIH and BMI at least 35. ICP improvement persisted over two years; the trial does
    not distinguish
    secretion from drainage mediation.
  evidence:
  - reference: PMID:33900360
    reference_title: 'Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this randomized clinical trial, bariatric surgery was superior to a CWM intervention
      in lowering
      intracranial pressure.
    explanation: >-
      The randomized IIH:WT trial supports sustained disease modification in the studied
      population.
  target_mechanisms:
  - target: Metabolic risk background
    treatment_effect: MODULATES
    description: >-
      Sustained surgically induced weight loss modifies the obesity-associated metabolic
      state.
    evidence:
    - reference: PMID:33900360
      reference_title: 'Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The continued improvement over the course of 2 years shows the impact of this
        intervention with
        regard to sustained disease remission.
      explanation: >-
        Supports durable benefit without establishing a unique hormonal mediator.
- name: CSF diversion surgery
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: CSF diversion surgery
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  description: >-
    Shunting diverts CSF to lower intracranial pressure when vision is threatened
    or medical treatment
    fails. Surgical selection and revision burden require specialist evaluation.
  evidence:
  - reference: PMID:10387332
    reference_title: Elevated intracranial pressure and pseudotumor cerebri.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS)
      may improve vision
      and prevent deterioration of vision in patients with PTC.
    explanation: >-
      Supports vision-protecting surgical options; comparative superiority is not
      established by this
      review.
  target_mechanisms:
  - target: Elevated intracranial pressure
    treatment_effect: MODULATES
    description: >-
      Shunting diverts CSF to lower intracranial pressure when vision is threatened
      or medical treatment
      fails. Surgical selection and revision burden require specialist evaluation.
    evidence:
    - reference: PMID:10387332
      reference_title: Elevated intracranial pressure and pseudotumor cerebri.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS)
        may improve vision
        and prevent deterioration of vision in patients with PTC.
      explanation: >-
        Supports vision-protecting surgical options; comparative superiority is not
        established by this
        review.
- name: Optic nerve sheath fenestration
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Optic nerve sheath fenestration
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  description: >-
    Fenestration decompresses the perioptic CSF compartment to protect vision in selected
    cases. It is
    not an established treatment for headache alone and does not necessarily normalize
    global ICP.
  evidence:
  - reference: PMID:10387332
    reference_title: Elevated intracranial pressure and pseudotumor cerebri.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS)
      may improve vision
      and prevent deterioration of vision in patients with PTC.
    explanation: >-
      Supports vision-protecting surgical options; comparative superiority is not
      established by this
      review.
  target_mechanisms:
  - target: Optic nerve axoplasmic transport impairment
    treatment_effect: MODULATES
    description: >-
      Fenestration decompresses the perioptic CSF compartment to protect vision in
      selected cases. It
      is not an established treatment for headache alone and does not necessarily
      normalize global ICP.
    evidence:
    - reference: PMID:10387332
      reference_title: Elevated intracranial pressure and pseudotumor cerebri.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Both optic nerve sheath fenestration (ONSF) and lumboperitoneal shunting (LPS)
        may improve vision
        and prevent deterioration of vision in patients with PTC.
      explanation: >-
        Supports vision-protecting surgical options; comparative superiority is not
        established by this
        review.
- name: Venous sinus stenting
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: venous sinus stenting
    term:
      id: NCIT:C157840
      label: Endovascular Stenting
  description: >-
    An option for selected medically refractory IIH with hemodynamically significant
    stenosis. Observational
    studies support pressure and visual improvement; thrombosis, hemorrhage, restenosis
    and retreatment
    are relevant limitations, and clinical response does not prove venous stenosis
    was the initiating
    lesion.
  evidence:
  - reference: PMID:37410913
    reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A growing body of evidence supports the use of venous sinus stenting as a viable
      option for medically
      refractory IIH, especially when papilledema threatens visual function.
    explanation: >-
      The evidence is largely nonrandomized and applies to selected patients with
      relevant venous stenosis.
  target_mechanisms:
  - target: Venous sinus stenosis
    treatment_effect: MODULATES
    description: >-
      Stenting expands the narrowed lumen and reduces the trans-stenotic pressure
      gradient.
    evidence:
    - reference: PMID:37410913
      reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        A growing body of evidence supports the use of venous sinus stenting as a
        viable option for medically
        refractory IIH, especially when papilledema threatens visual function.
      explanation: >-
        The evidence is largely nonrandomized and applies to selected patients with
        relevant venous stenosis.
- name: Topiramate
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: topiramate
      term:
        id: CHEBI:63631
        label: topiramate
  description: >-
    Used off label for IIH, particularly when migraine-like headache and weight management
    are relevant.
    Evidence includes a small open-label comparison with acetazolamide; potential
    visual benefit and weight
    loss do not establish superiority or a proven ICP effect in that study.
  evidence:
  - reference: PMID:17922725
    reference_title: 'Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      When the follow-up visual field grades were compared with the visual field grades
      at the beginning
      of the study in each group a statistically significant improvement was detected
      with both drugs.
    explanation: >-
      A small open-label comparison supports potential benefit of topiramate and acetazolamide,
      without
      proving equivalence or superiority.
  target_mechanisms:
  - target: Choroid plexus CSF hypersecretion
    treatment_effect: INHIBITS
    description: >-
      Carbonic anhydrase inhibition is a proposed secretion-reducing action; the open-label
      clinical study
      did not isolate the mechanism.
    evidence:
    - reference: PMID:17922725
      reference_title: 'Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Weight reduction as well as the reduction of the CSF formation is the possible
        mechanism of action.
      explanation: >-
        The source explicitly presents the mechanism as possible, not directly measured.
      directness: INDIRECT
- name: Erenumab for persistent headache in ocular remission
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: erenumab
      term:
        id: NCIT:C169958
        label: Erenumab
  description: >-
    Investigated for persistent chronic headache after papilledema has resolved. The
    prospective open-label
    evidence supports headache reduction in this specific setting; it must not be
    interpreted as treatment
    of raised ICP or prevention of visual injury.
  evidence:
  - reference: PMID:33316102
    reference_title: 'Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study provides evidence for the effectiveness of erenumab to treat headaches
      in IIH patients
      with resolution of papilledema.
    explanation: >-
      The 55-woman prospective open-label study supports symptomatic benefit in ocular
      remission, without
      establishing pressure lowering or visual protection.
  target_mechanisms:
  - target: CGRP-mediated trigeminovascular headache signaling
    treatment_effect: INHIBITS
    description: >-
      CGRP-receptor blockade targets the headache pathway; surveillance for recurrent
      papilledema remains
      necessary regardless of headache relief.
    evidence:
    - reference: PMID:33316102
      reference_title: 'Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This study provides evidence for the effectiveness of erenumab to treat headaches
        in IIH patients
        with resolution of papilledema.
      explanation: >-
        The 55-woman prospective open-label study supports symptomatic benefit in
        ocular remission, without
        establishing pressure lowering or visual protection.
diagnosis:
- name: Brain MRI and venography
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  description: >-
    Brain imaging excludes structural causes, and CT or MR venography excludes cerebral
    venous thrombosis.
    Empty sella, optic nerve sheath distension and sinus narrowing can support the
    assessment but are
    not independently diagnostic.
  results: Normal brain imaging without mass lesion supports IIH after exclusion of secondary causes.
  evidence:
  - reference: PMID:30298346
    reference_title: European headache federation guideline on idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diagnostic brain imaging in IIH should always include a CT- or MR venography
    explanation: >-
      Supports venous imaging in addition to brain MRI; the surrounding recommendation
      specifies exclusion
      of venous thrombosis.
- name: Lumbar puncture with opening pressure measurement
  description: >-
    After appropriate imaging, lumbar puncture documents opening pressure and CSF
    composition. Adult pressure
    above 25 cm CSF supports IIH in the complete clinical context; pediatric thresholds
    and sedation require
    age-specific interpretation. A single borderline result is not independently diagnostic.
  results: Elevated opening pressure with normal CSF composition supports the diagnosis.
  evidence:
  - reference: PMID:12455560
    reference_title: Diagnostic criteria for idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The syndrome of increased intracranial pressure without hydrocephalus or mass
      lesion and with normal
      CSF composition
    explanation: This directly supports lumbar puncture-based confirmation of pressure elevation with normal CSF composition.
  - reference: PMID:23966248
    reference_title: Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      clarification of normal opening pressure in children, and features distinguishing
      the syndrome of
      intracranial hypertension without papilledema from intracranial hypertension
      with papilledema
    explanation: >-
      Revised criteria distinguish pediatric pressure interpretation and the rare
      presentation without
      papilledema.
- name: Neuro-ophthalmic examination and formal perimetry
  description: >-
    Confirm papilledema, distinguish pseudopapilledema, and document visual acuity,
    pupils, fundus appearance
    and formal visual fields. OCT helps monitor optic nerve head swelling, but central
    acuity alone can
    miss functionally relevant field loss.
  evidence:
  - reference: PMID:24756302
    reference_title: 'The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with IIH with mild visual loss have typical symptoms, may have mild
      acuity loss, and have
      visual field defects, with predominantly arcuate loss and enlarged blind spots
      that require formal
      perimetry for detection.
    explanation: >-
      Supports formal perimetry rather than relying on acuity alone.
differential_diagnoses:
- name: Cerebral sinovenous thrombosis
  disease_term:
    preferred_term: cerebral sinovenous thrombosis
    term:
      id: MONDO:0017993
      label: cerebral sinovenous thrombosis
  description: >-
    Venous sinus thrombosis can mimic IIH with papilledema and raised intracranial
    pressure and must be
    excluded on imaging.
  evidence:
  - reference: PMID:30298346
    reference_title: European headache federation guideline on idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diagnostic brain imaging in IIH should always include a CT- or MR venography
    explanation: >-
      Supports venous imaging in addition to brain MRI; the surrounding recommendation
      specifies exclusion
      of venous thrombosis.
- name: Brain neoplasm
  disease_term:
    preferred_term: brain neoplasm
    term:
      id: MONDO:0021211
      label: brain neoplasm
  description: >-
    Intracranial mass lesions must be excluded before the diagnosis of pseudotumor
    cerebri is made.
  evidence:
  - reference: PMID:12455560
    reference_title: Diagnostic criteria for idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The syndrome of increased intracranial pressure without hydrocephalus or mass
      lesion and with normal
      CSF composition, previously referred to as pseudotumor cerebri, is a diagnosis
      of exclusion now
      termed idiopathic intracranial hypertension (IIH).
    explanation: This directly supports exclusion of mass lesions such as brain neoplasms when diagnosing pseudotumor cerebri.
- name: Secondary medication-associated intracranial hypertension
  description: >-
    An identifiable medication or other secondary cause changes the diagnosis from
    primary IIH to secondary
    pseudotumor cerebri syndrome. Medication review and investigation of atypical
    presentations are part
    of excluding secondary disease.
  evidence:
  - reference: PMID:23966248
    reference_title: Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The pseudotumor cerebri syndrome (PTCS) may be primary (idiopathic intracranial
      hypertension) or
      arise from an identifiable secondary cause.
    explanation: >-
      Supports the required primary-versus-secondary distinction.
clinical_trials:
- name: NCT01003639
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Randomized placebo-controlled IIHTT trial testing acetazolamide plus low-sodium
    weight-reduction diet
    in patients with mild visual loss.
  target_phenotypes:
  - preferred_term: Visual loss
    term:
      id: HP:0000572
      label: Visual loss
  - preferred_term: Papilledema
    term:
      id: HP:0001085
      label: Papilledema
  evidence:
  - reference: clinicaltrials:NCT01003639
    reference_title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This trial will study subjects who have mild visual loss from IIH to (1) establish
      convincing, evidence-based
      treatment strategies for IIH to restore and protect vision, (2) follow subjects
      up to 4 years to
      observe the long-term treatment outcomes and (3) determine the cause of IIH.
    explanation: The registered IIHTT trial directly targeted visual outcomes in IIH.
- name: NCT02124486
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    IIH:WT randomized comparison of bariatric surgery versus community weight management
    in women with
    BMI at least 35. Primary and two-year results are published; the registry currently
    gives overall
    status UNKNOWN for the extended study.
  evidence:
  - reference: PMID:33900360
    reference_title: 'Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02124486.
    explanation: >-
      Connects the published randomized bariatric trial to its registered identifier.
  - reference: clinicaltrials:NCT02124486
    reference_title: 'A Randomised Controlled Trial of Bariatric Surgery Versus a Community Weight Loss Programme for the Sustained Treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial'

    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Participants will then be followed up for five years, with the most important measurement being their brain pressure after one year of being in the trial.
    explanation: >-
      The registry records the planned follow-up and study design. Published
      results supply the efficacy evidence; this protocol text is not a result.

- name: NCT02017444
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Completed AZD4017 trial; the primary between-group ICP endpoint was not significant.
  evidence:
  - reference: PMID:28923789
    reference_title: 'Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      IIH:DT is the first phase II double-blind randomized placebo-controlled trial
      assessing the efficacy
      and safety of the novel pharmacological intervention, AZD4017, for the treatment
      of IIH.
    explanation: >-
      Identifies the AZD4017 phase II trial whose registration is NCT02017444.
  - reference: clinicaltrials:NCT02017444
    reference_title: "Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study."

    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Eligible participants will be randomly assigned to AZD4017 or a placebo ('dummy' with no active drug) for 3 months with a follow up a month later.
    explanation: >-
      The registry records the planned follow-up and study design. Published
      results supply the efficacy evidence; this protocol text is not a result.

- name: ISRCTN12678718
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Completed IIH:Pressure exenatide randomized trial with telemetric ICP measurements;
    clinical findings
    remain preliminary.
  evidence:
  - reference: ICTRP:ISRCTN12678718
    reference_title: IIH Pressure - a new treatment for raised brain pressure in Idiopathic Intracranial Hypertension
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Target sample size | 16
    explanation: >-
      The registry records the 16-participant exenatide trial.
- name: NCT05347147
  phase: PHASE_III
  status: TERMINATED
  description: >-
    IIH EVOLVE trial of sustained-release exenatide (Presendin). The registry reports
    termination after
    the sponsor judged continuation not viable; it does not supply confirmatory phase
    III efficacy. Registry
    status checked during the September 2026 review.
  evidence:
  - reference: clinicaltrials:NCT05347147
    reference_title: A Phase III Randomised, Placebo-controlled, Double-blind, Multi-centre, Clinical Trial to Determine the Efficacy and Safety of Presendin in Idiopathic Intracranial Hypertension
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This trial has been designed to evaluate the efficacy and safety of a new formulation
      of exenatide
      (Presendin) in the reduction of intracranial pressure (ICP) in patients with
      IIH.
    explanation: >-
      The registry establishes the investigational phase III program, not a successful
      efficacy result.
mechanistic_hypotheses:
- hypothesis_group_id: choroid_plexus_csf_hypersecretion
  hypothesis_label: Choroid Plexus CSF Hypersecretion (Metabolic-Hormonal) Model
  status: EMERGING
  description: >-
    Metabolic and hormonal abnormalities may contribute to raised ICP through choroid
    plexus secretion
    in a subset of IIH. Human androgen excess and rodent perturbations support plausibility,
    but direct
    human secretion measurements and causal ordering remain unresolved. GLP-1 receptor
    agonism suppresses
    secretory transport in preclinical systems and lowers ICP in a small randomized
    trial; endogenous
    GLP-1 deficiency has not been established. The AZD4017 trial did not meet its
    primary between-group
    endpoint. Impaired outflow, intrinsic venous lesions, and pressure-dependent venous
    feedback may act
    in parallel or dominate in other patients.
  evidence:
  - reference: PMID:30753168
    reference_title: A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Women with IIH showed a pattern of androgen excess distinct to that observed
      in PCOS and simple
      obesity, with increased serum testosterone and increased CSF testosterone and
      androstenedione.
    explanation: >-
      Human steroid profiling demonstrates an association in adult women; it does
      not establish that androgen
      excess initiates raised pressure.
  - reference: PMID:37328884
    reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%)
      and CSF secretion
      rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter,
      NKCC1.
    explanation: >-
      Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated
      mechanism;
      human IIH secretion was not measured.
  - reference: PMID:36907221
    reference_title: 'The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Exenatide significantly and meaningfully lowered intracranial pressure at 2.5
      h -5.7 ± 2.9 cmCSF
      (P = 0.048); 24 h -6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks -5.6 ± 3.0 cmCSF
      (P = 0.058).
    explanation: >-
      The small randomized trial supports ICP lowering; alpha was prespecified at
      0.1 and direct CSF secretion
      was not measured.
  - reference: PMID:32954315
    reference_title: '11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 12 weeks, lumbar puncture pressure was lower in the AZD4017 group (29.7 cmH2O)
      compared with
      placebo (31.3 cmH2O), but the difference between groups was not statistically
      significant (mean
      difference: -2.8, 95% confidence interval: -7.1 to 1.5; P = 0.2).
    explanation: >-
      The primary between-group endpoint did not establish efficacy; exploratory within-group
      changes
      and biomarker correlations cannot substitute for that comparison.
  - reference: PMID:40937960
    reference_title: 'Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No association was detected between GLP-1 RAs and body mass index.
    explanation: >-
      Across 1550 patients pooled from one randomized trial, one non-randomized case-control
      study and
      two registries, incretin treatment was associated with lower papilledema and
      visual-disturbance
      risk without a detectable body mass index effect, which is the pattern a direct
      action on secretory
      transport predicts. A pooled null for one covariate is not a mediation analysis,
      the registries
      dominate the sample, and the pooled agents include dual GIP/GLP-1 receptor agonists
      rather than
      exenatide alone, so this weakens the weight-loss explanation without establishing
      the secretory one.
    directness: INDIRECT
  notes: >-
    Retain EMERGING. OpenScientist correctly argues against promoting a single primary
    hypersecretion
    model, but overstates several supporting claims: chronic testosterone activated
    NKCC1 rather than
    Na+/K+-ATPase in PMID:37328884, intrinsic stenosis proportions come from a selected
    stenting cohort,
    and pharmacological response does not establish the untreated initiating lesion.
    The assessment sidecar
    records these and other source-level qualifications.
- hypothesis_group_id: primary_venous_sinus_obstruction
  hypothesis_label: Primary Venous Sinus Obstruction Model
  status: ALTERNATIVE
  description: >-
    A venous contribution can arise from intrinsic transverse-sigmoid narrowing or
    pressure-dependent
    extrinsic compression. A significant gradient can sustain venous hypertension
    and impaired CSF outflow,
    with ICP-dependent narrowing closing a feedback loop. Stenting responses support
    a modifiable hemodynamic
    contributor in selected patients but do not establish that venous obstruction
    initiates every case.
  evidence:
  - reference: PMID:37410913
    reference_title: 'Idiopathic Intracranial Venous Hypertension: Toward a Better Understanding of Venous Stenosis and the Role of Stenting in Idiopathic Intracranial Hypertension.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Venous sinus stenosis, typically at the junction of the transverse and sigmoid
      sinus, is increasingly
      recognized as a contributor to the pathophysiology of idiopathic intracranial
      hypertension (IIH),
      whether it be the intrinsic type that does not reverse with normalization of
      intracranial pressure
      or the extrinsic type, which does.
    explanation: >-
      Intrinsic and pressure-responsive extrinsic lesions are distinct morphologies;
      persistence alone
      does not prove that the lesion preceded IIH.
- hypothesis_group_id: glymphatic_isf_dyshomeostasis
  hypothesis_label: Glymphatic and Interstitial Fluid Dyshomeostasis Model
  status: ALTERNATIVE
  description: >-
    A competing model places the primary fluid disturbance in interstitial fluid clearance
    rather than
    in CSF secretion. Obesity-associated metabolic dysfunction is proposed to impair
    glymphatic clearance,
    interstitial fluid then accumulates, brain volume rises, and the swollen parenchyma
    compresses the
    dural venous sinuses from outside, with the resulting venous hypertension feeding
    back on glymphatic
    drainage. It accommodates the rat paradigm in which high-fat feeding raises ICP
    with the CSF secretion
    rate unchanged, but it is argued from narrative synthesis and cross-sectional imaging
    surrogates,
    and glymphatic function in patients has so far been assessed only through an imaging
    index rather
    than measured directly.
  evidence:
  - reference: PMID:41472646
    reference_title: 'A unifying disease model of idiopathic intracranial hypertension: A narrative review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      We propose a unified disease model where obesity-mediated metabolic dysfunction results in impaired glymphatic clearance with consequential accumulation of brain ISF with resultant increased brain volume.
    explanation: >-
      States the alternative causal ordering in the proposing authors' own words.
      It is a narrative
      review advancing a framework rather than a primary result, so it establishes
      that the model is
      seriously argued in the literature and not that it is correct.
  - reference: PMID:39585390
    reference_title: Optic Nerve Sheath Dilation Is a Possible Marker of CSF Dyshomeostasis in Idiopathic Intracranial Hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, increasing PSAS/ONSD was associated with declining/worsening cerebral glymphatic clearance based on DTI-APLS (p = 0.043, R = 0.34).
    explanation: >-
      The closest patient-level observation the model currently has: in 55 retrospectively
      identified
      IIH patients a marker of perioptic CSF distension tracked a lower DTI-ALPS index.
      DTI-ALPS is
      a diffusion surrogate rather than a clearance measurement, the association is
      weak and cross-sectional,
      and the same regression associated the marker with larger choroid plexus volume,
      so it does not
      separate this model from choroid plexus hypersecretion.
    directness: INDIRECT
  notes: >-
    Recorded as ALTERNATIVE rather than EMERGING because the mechanism rests on narrative
    synthesis
    and correlational imaging surrogates, with no interventional study and no direct
    clearance measurement
    in IIH. The hypothesis assessment sidecar dispositions the unifying glymphatic
    claim as QUALIFIED
    and asks that it be preserved as an explicit hypothesis rather than a canonical
    causal chain, which
    is the form used here. No pathophysiology node asserts impaired glymphatic clearance,
    so no causal
    edge opts into this group; separating it from the secretory model needs paired secretion-rate
    and
    clearance measurement in the same patients.
discussions:
- discussion_id: gap_iih_headache_mechanism
  prompt: >-
    What is the proximate mechanism of headache in IIH, and why is it imperfectly
    coupled to the degree
    of intracranial pressure elevation?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Headache syndrome
  - pathophysiology#CGRP-mediated trigeminovascular headache signaling
  rationale: >-
    Headache is the dominant symptomatic morbidity but its mechanism is only partly
    understood. Human
    CGRP provocation data now support trigeminovascular neuropeptide signaling and
    ICP pulsatility as
    a proximal mechanism, while headache can still persist or fluctuate independently
    of measured pressure.
    Modeling headache purely as a downstream consequence of raised mean pressure remains
    incomplete.
- discussion_id: gap_iih_venous_stenosis_cause_or_consequence
  prompt: >-
    Is transverse venous sinus stenosis a primary initiating lesion or a pressure-dependent
    feedback consequence
    in IIH?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Venous sinus stenosis
  - pathophysiology#Dysregulated cerebrospinal fluid dynamics
  - pathophysiology#Elevated intracranial pressure
  rationale: >-
    Transverse sinus stenosis is present in most patients and venous sinus stenting
    helps a subset, yet
    stenosis can reverse once intracranial pressure is lowered. Whether it initiates
    the disease or amplifies
    an already-elevated-pressure state is unresolved and distinguishes the primary
    venous obstruction
    model from the choroid plexus hypersecretion model.
- discussion_id: gap_iih_sex_and_nonobese_predilection
  prompt: >-
    Why does IIH predominantly affect obese women of reproductive age, and what distinguishes
    the mechanism
    in non-obese or atypical cases?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Metabolic risk background
  - pathophysiology#Choroid plexus CSF hypersecretion
  rationale: >-
    Sex and metabolic associations do not explain all IIH presentations. Pediatric,
    male, and non-obese
    populations require separate evaluation; medication-related raised ICP is a secondary
    cause to exclude,
    not evidence for an idiopathic non-obese subtype.
- discussion_id: gap_iih_obesity_venous_csf_hierarchy
  prompt: >-
    How do obesity/metabolic-hormonal drivers, venous sinus pressure and stenosis,
    and CSF production/absorption
    interact causally in IIH, and which of these is the initiating event versus an
    amplifying feedback
    consequence?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Metabolic risk background
  - pathophysiology#Choroid plexus CSF hypersecretion
  - pathophysiology#Venous sinus stenosis
  - pathophysiology#Dysregulated cerebrospinal fluid dynamics
  rationale: >-
    IIH is defined by raised intracranial pressure without a mass lesion, yet the
    causal ordering among
    its candidate mechanisms remains unresolved. Multiple pathways have been proposed
    as the underlying
    cause - choroid plexus CSF overproduction, impaired CSF outflow/absorption, elevated
    venous sinus
    pressure with transverse sinus stenosis, glymphatic dysfunction, and obesity-associated
    hormonal alterations
    - but no single theory explains the entire clinical picture. The metabolic-hormonal
    arm is an attractive
    upstream driver because pharmacological modulation lowers intracranial pressure,
    yet the AZD4017 trial
    missed its primary endpoint and the human evidence linking specific hormonal axes
    to choroid plexus
    secretion is still maturing. Venous sinus stenosis is present in most patients
    and stenting helps
    a subset, but stenosis frequently reverses once pressure is lowered, so it may
    amplify rather than
    initiate the disease via a positive feedback loop. There is even emerging argument
    that CSF overproduction
    is unlikely to be the primary driver and that carbonic-anhydrase inhibition targets
    a consequence
    rather than the cause. Disentangling which node is initiating versus secondary
    across obese, non-obese,
    and atypical patients is the central unresolved question and would reorder the
    entire pathophysiology
    causal graph and its therapeutic targets.
  proposed_experiments:
  - experiment_id: exp_iih_mechanism_perturbation_ordering
    name: Interventional perturbation cohort to order metabolic, venous, and CSF mechanisms
    description: >-
      Enroll newly diagnosed IIH patients (obese and non-obese strata) and apply mechanism-specific
      perturbations
      with simultaneous multi-axis monitoring.
    experiment_type:
      preferred_term: prospective interventional mechanistic cohort study
    readouts:
    - name: Metabolic-hormonal response and intracranial pressure
      target: pathophysiology#Metabolic risk background
      description: >
        Quantify circulating metabolic and hormonal markers and body composition alongside
        intracranial
        pressure during a metabolic-hormonal intervention.
      assays:
      - preferred_term: serum hormone quantification
      - preferred_term: lumbar puncture opening pressure measurement
      direction: NEGATIVE
    - name: CSF secretion response to carbonic anhydrase inhibition
      target: pathophysiology#Choroid plexus CSF hypersecretion
      description: >
        Measure intracranial pressure and CSF dynamics before and after carbonic anhydrase
        inhibition.
      assays:
      - preferred_term: cerebrospinal fluid dynamics assessment
      direction: NEGATIVE
    - name: Trans-stenosis gradient and pressure coupling
      target: pathophysiology#Venous sinus stenosis
      description: >
        Measure the transverse-sinus trans-stenosis pressure gradient before and after
        intracranial pressure
        is lowered, and before and after stenting.
      assays:
      - preferred_term: catheter cerebral venography pressure gradient measurement
      direction: POSITIVE
    decision_criterion: >-
      A pathway is supported as a modifiable mediator if its perturbation reproducibly
      changes the expected
      direct readout and ICP after accounting for weight loss, venous pressure, and
      outflow compensation.
      Improvement alone does not identify the initiating lesion; causal ordering additionally
      requires
      temporally resolved measurements before disease onset or a justified causal
      mediation design.
    would_support:
    - pathophysiology#Metabolic risk background
    - pathophysiology#Choroid plexus CSF hypersecretion
    - pathophysiology#Venous sinus stenosis
  evidence:
  - reference: PMID:33631966
    reference_title: Diagnosis and treatment of idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Several mechanisms have been proposed as the underlying cause of IIH, such as
      an overproduction
      of cerebrospinal fluid (CSF), outflow obstruction, elevated pressure in the
      venous sinuses and more
      recently a dysfunction in the glymphatic pathway as well as hormonal alterations.
    explanation: >-
      Directly enumerates the competing candidate mechanisms whose causal ordering
      is unresolved.
  - reference: PMID:26700907
    reference_title: 'Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Pathogenesis has not been fully elucidated, but several causal factors have
      been proposed.
    explanation: >-
      Confirms that the pathogenesis and causal ordering of the proposed factors remain
      unestablished.
- discussion_id: gap_iih_secretory_transport_and_outflow_translation
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: Do the distinct secretory and drainage changes in rodent models occur in the same human IIH subgroups?
  attaches_to:
  - pathophysiology#Choroid plexus CSF hypersecretion
  - pathophysiology#Impaired cerebrospinal fluid outflow
  rationale: >-
    Rodent findings differ by strain, diet, hormonal perturbation, and assay: one
    high-fat paradigm increases
    secretion, another increases outflow resistance, and obese Zucker rats compensate
    for testosterone-induced
    secretion. Human androgen excess and drug-induced ICP reduction are insufficient
    to resolve the dominant
    human pathway. MRI water exchange and aqueductal flow must be validated against
    net secretion before
    being treated as direct production measurements.
  evidence:
  - reference: PMID:37328884
    reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      HFD-fed rats presented with increased ICP (65%), which was accompanied by increased
      CSF outflow
      resistance (50%) without altered CSF secretion rate or choroid plexus gene expression.
    explanation: >-
      High-fat feeding elevates ICP through drainage resistance in this rat paradigm,
      providing an alternative
      to obligatory hypersecretion.
  - reference: PMID:38273331
    reference_title: CSF hyperdynamics in rats mimicking the obesity and androgen excess characteristic of patients with idiopathic intracranial hypertension.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Adjuvant testosterone treatment of obese rats elevated the CSF secretion rate,
      although with no
      effect on the ICP, due to elevated CSF drainage capacity of these rats.
    explanation: >-
      Compensatory drainage prevents ICP elevation despite higher secretion, showing
      that secretion is
      not sufficient in every model.
  - reference: PMID:41279197
    reference_title: Indirect Deuterium Displacement Exchange Imaging for Noninvasive High-Resolution CSF Production Mapping.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using high-resolution 3D balanced steady-state free precession MRI in rats, we demonstrate robust and spatially widespread D2O-induced CSF signal loss that is selectively suppressed by acetazolamide, a carbonic anhydrase inhibitor known to suppress CSF production by the choroid plexus.
    explanation: >-
      Shows what the validation this gap demands looks like: a noninvasive production
      readout anchored
      to pharmacological suppression of secretion rather than assumed from water exchange.
      It is a rat
      study and a preprint that has not been peer reviewed, so it makes the human
      measurement a translation
      problem rather than an unsolved methodological one, and it does not itself measure
      anything in IIH.
- discussion_id: gap_iih_genetic_susceptibility
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: Which genetic susceptibility findings replicate in larger, independently phenotyped IIH cohorts?
  attaches_to:
  - disease#pseudotumor cerebri
  rationale: >-
    The earlier NORDIC IIHTT GWAS and later small familial haplotype study generate
    candidates but do
    not establish a Mendelian IIH gene or a genome-wide significant causal locus.
    The familial study’s
    P<0.01 exploratory threshold and relatedness/age imbalance require replication.
    Its CA5A candidate
    cannot be treated as proof that mitochondrial carbonic anhydrase drives choroid
    plexus secretion.
  evidence:
  - reference: PMID:29608535
    reference_title: Genetic Survey of Adult-Onset Idiopathic Intracranial Hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The study was limited by its modest size and thus would have only been able
      to demonstrate highly
      significant association on a genome-wide scale for relatively common alleles
      exerting large effects.
    explanation: >-
      The first rigorous IIHTT GWAS identifies a power limitation, not a definitive
      causal gene.
  - reference: PMID:38528581
    reference_title: 'A genetic survey of patients with familial idiopathic intracranial hypertension residing in a Middle Eastern village: genetic association study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Samples from 22 female participants (11 patients and 11 controls) were evaluated
      for haplotype clustering
      and genome-wide association studies (GWAS).
    explanation: >-
      Defines the actual small analyzed cohort rather than conflating it with all
      recruited subjects.
notes: >-
  The metabolic-hormonal pathograph is scoped to primary IIH, especially the adult
  female populations
  studied. Pseudotumor cerebri syndrome also includes secondary intracranial hypertension,
  including medication-associated
  disease and cerebral venous thrombosis; these must be excluded before the idiopathic
  label is applied.
  Candidate secretory, drainage, and venous mechanisms are not validated clinical
  subtypes. The OpenScientist
  report was reviewed against primary sources; its supported leads and qualifications
  are represented
  below, with claim-level judgments in the hypothesis assessment sidecar.
animal_models:
- name: High-fat-fed female Wistar rat
  species: Rattus norvegicus
  description: >-
    Twenty-one-week high-fat diet model with increased ICP and outflow resistance,
    without increased secretion
    in this paradigm.
  publication: PMID:37328884
  modeled_mechanisms:
  - target: Impaired cerebrospinal fluid outflow
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Diet-induced rat physiology does not establish the initiating lesion in human
      IIH; other high-fat
      paradigms yield different secretion results.
    evidence:
    - reference: PMID:37328884
      reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        HFD-fed rats presented with increased ICP (65%), which was accompanied by increased
        CSF outflow
        resistance (50%) without altered CSF secretion rate or choroid plexus gene expression.
      explanation: >-
        High-fat feeding elevates ICP through drainage resistance in this rat paradigm,
        providing an alternative
        to obligatory hypersecretion.
    readouts:
    - name: CSF outflow resistance
      target: Impaired cerebrospinal fluid outflow
      direction: INCREASED
      evidence:
      - reference: PMID:37328884
        reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          HFD-fed rats presented with increased ICP (65%), which was accompanied by increased
          CSF outflow
          resistance (50%) without altered CSF secretion rate or choroid plexus gene expression.
        explanation: >-
          High-fat feeding elevates ICP through drainage resistance in this rat paradigm,
          providing an alternative
          to obligatory hypersecretion.
- name: Testosterone-treated female Wistar rat
  species: Rattus norvegicus
  description: >-
    Chronic adjuvant testosterone model with NKCC1-associated increased CSF secretion
    and ICP.
  publication: PMID:37328884
  modeled_mechanisms:
  - target: Choroid plexus CSF hypersecretion
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Exogenous testosterone and rodent CSF transport cannot establish endogenous
      human IIH causation.
    evidence:
    - reference: PMID:37328884
      reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%)
        and CSF secretion
        rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter,
        NKCC1.
      explanation: >-
        Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated
        mechanism;
        human IIH secretion was not measured.
    readouts:
    - name: CSF secretion rate
      target: Choroid plexus CSF hypersecretion
      direction: INCREASED
      evidence:
      - reference: PMID:37328884
        reference_title: 'Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Chronic adjuvant testosterone treatment of lean rats caused elevated ICP (55%)
          and CSF secretion
          rate (85%), in association with increased activity of the choroid plexus Na+,K+,2Cl- cotransporter,
          NKCC1.
        explanation: >-
          Chronic testosterone increases secretion and ICP in female rats through an NKCC1-associated
          mechanism;
          human IIH secretion was not measured.
- name: Testosterone-treated obese female Zucker rat
  species: Rattus norvegicus
  description: >-
    A compensating model in which secretion rises but ICP does not, because drainage
    capacity also rises.
  publication: PMID:38273331
  modeled_mechanisms:
  - target: Elevated intracranial pressure
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: ORGANISM
    limitations: >-
      Enhanced drainage prevents the elevated-ICP phenotype despite testosterone-induced
      hypersecretion.
    evidence:
    - reference: PMID:38273331
      reference_title: CSF hyperdynamics in rats mimicking the obesity and androgen excess characteristic of patients with idiopathic intracranial hypertension.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Adjuvant testosterone treatment of obese rats elevated the CSF secretion rate,
        although with no
        effect on the ICP, due to elevated CSF drainage capacity of these rats.
      explanation: >-
        Compensatory drainage prevents ICP elevation despite higher secretion, showing
        that secretion is
        not sufficient in every model.
    readouts:
    - name: Intracranial pressure
      target: Elevated intracranial pressure
      direction: UNCHANGED
      evidence:
      - reference: PMID:38273331
        reference_title: CSF hyperdynamics in rats mimicking the obesity and androgen excess characteristic of patients with idiopathic intracranial hypertension.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Adjuvant testosterone treatment of obese rats elevated the CSF secretion rate,
          although with no
          effect on the ICP, due to elevated CSF drainage capacity of these rats.
        explanation: >-
          Compensatory drainage prevents ICP elevation despite higher secretion, showing
          that secretion is
          not sufficient in every model.
references:
- reference: PMID:24756514
  title: 'Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.'
- reference: PMID:29903905
  title: 'Idiopathic intracranial hypertension: consensus guidelines on management.'
📚

References & Deep Research

References

2
PMID:24756514
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
No top-level findings curated for this source.
PMID:29903905
Idiopathic intracranial hypertension: consensus guidelines on management.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of pseudotumor cerebri. Core disease mechanisms, molecular and cellular pathw...
Asta Scientific Corpus Retrieval 20 citations 2026-04-13T13:54:04.205511

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of pseudotumor cerebri. Core disease mechanisms, molecular and cellular pathw...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

  • Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
  • Year: 2025
  • Venue: Journal of Veterinary Internal Medicine
  • URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
  • DOI: 10.1111/jvim.70139
  • PMID: 40492724
  • PMCID: 12150350
  • Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.364) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[2] Molecular Mechanisms and Risk Factors for the Pathogenesis of Hydrocephalus

  • Authors: Jing-wen Li, Xinjie Zhang, Jianfeng Guo, Chen Yu, Jun Yang
  • Year: 2022
  • Venue: Frontiers in Genetics
  • URL: https://www.semanticscholar.org/paper/d53bdf5f73f54a6d5a8be8777d23c465a13e9185
  • DOI: 10.3389/fgene.2021.777926
  • PMID: 35047005
  • PMCID: 8762052
  • Citations: 15
  • Influential citations: 2
  • Summary: Some possible fundamental molecular mechanisms and facilitating risk factors involved in the pathogenesis of hydrocephalus are elicited, and knowledge could be used to improve patient care in different ways, such as early precise diagnosis and effective therapeutic regimens.
  • Evidence snippets:
  • Snippet 1 (score: 0.361) > Cwh43 modifies the glycosylphosphatidylinositol-anchored proteins on the ependymal cells, and the mutant Cwh43 is related to iNPH in both humans and mice. The clinical features manifest as late-onset communicating hydrocephalus with symptoms of gait and balance dysfunction (Yang et al., 2021a). > The clinical manifestation and progression, as well as experimental investigations, indicate that hydrocephalus is a complex disease with polygenic involvement, rather than a simple CSF accumulation disorder. Although the current studies have revealed that some genetic mutations are involved in the pathogenesis of hydrocephalus, how these mutations are associated with the disorder of CSF circulation and their pathogenic roles in the pathological progression of hydrocephalus still remain largely unknown. Previous studies indicated that a lot of genetic mutations were relevant to the disorders of ciliary and/or centrosome, resulting in the dysfunction of the glymphatic system. However, how these mutations and their interactions contribute to the pathogenesis of hydrocephalus needs to be further elucidated. Moreover, there is still a lack of basic knowledge on the mechanisms underlying the cognitive functional impairment of hydrocephalus. Therefore, further extensive studies should be conducted to explore the underlying molecular mechanisms of identified and/or unidentified genes in the pathophysiology of hydrocephalus. Based on our knowledge, we propose that the genetic mutations relevant to ciliary and centrosomal proteins and the interaction between glymphatic system and ciliary/ centrosomal structures/functions may be a critical molecular mechanism in the pathophysiology of hydrocephalus. In addition, based on these fundamental molecular mechanisms, it is noteworthy that environmental and other acquired risks or etiological factors are also involved in the facilitation of ventricular enlargement.

[3] Molecular and cellular characteristics of cerebrovascular cell types and their contribution to neurodegenerative diseases

  • Authors: F. J. García, Myriam Heiman
  • Year: 2025
  • Venue: Molecular Neurodegeneration
  • URL: https://www.semanticscholar.org/paper/651ecb2269ae562236345f2451cab13e3d495216
  • DOI: 10.1186/s13024-025-00799-z
  • PMID: 39881338
  • PMCID: 11780804
  • Citations: 6
  • Summary: The current understanding of cerebrovasculature structure, function, and cell type diversity and its role in the mechanisms underlying various neurodegenerative diseases is described.
  • Evidence snippets:
  • Snippet 1 (score: 0.356) > Aging-associated neurodegenerative diseases exhibit distinct patterns of enhanced vulnerability, whereby specific populations of neurons are earliest and most affected in each disease [1]. Disease symptoms and progression, in turn, reflect the dysfunction of these most vulnerable cell types and associated circuits. In many cases, it is not into the molecular basis underlying cell structure and function [4][5][6][7]. Furthermore, single cell studies of specific neurodegenerative diseases have focused on profiling cells in the affected brain regions to understand cell type-specific dysregulation with the potential of uncovering disease-relevant gene expression patterns that could lead into the development of novel therapeutic strategies [8][9][10][11][12]. These studies have highlighted the interplay between affected neurons and other cell types of the brain, especially with identification of disease-associated genes that are enriched in non-neuronal cell populations, such as microglia and cerebrovascular cell types [13,14]. > In recent years, the cerebrovasculature and its role in the pathophysiology of neurodegenerative diseases has become a topic of considerable research focus. Despite extensive clinical data documenting functional changes in cerebrovascular function, especially at early stages of disease, the precise cellular and molecular mechanisms underlying these changes, particularly in humans, are not fully understood. Common themes of cerebrovasculature dysfunction, such as aberrant angiogenesis, decreases in tight junction expression, and increased transcytosis, have been noted, but the exact contributions of specific cerebrovascular cell types, and more importantly, their causal contribution to disease mechanisms are unknown. However, with the advent of a single cell atlas of the mouse cerebrovasculature, a framework for studying the molecular profiles of cerebrovascular cell types has been recently established [15]. This work provided a reference for several subsequent human atlases and the corresponding molecular changes within these cell types that occur across development and disease [14,[16][17][18][19][20]. > This review focuses on our current understanding of cerebrovasculature structure and function and its role in neurodegenerative diseases.

[4] Organoids in gastrointestinal diseases: from bench to clinic

  • Authors: Qinying Wang, Fanying Guo, Qinyuan Zhang, Tingting Hu, Yutao Jin et al.
  • Year: 2024
  • Venue: MedComm
  • URL: https://www.semanticscholar.org/paper/9b8880d8b9d45670da950197d7e353794f51d09e
  • DOI: 10.1002/mco2.574
  • PMID: 38948115
  • PMCID: 11214594
  • Citations: 12
  • Summary: A comprehensive and systematical depiction of organoids models is drawn, providing a novel insight into the utilization of organoids models from bench to clinic and clinical adhibition.
  • Evidence snippets:
  • Snippet 1 (score: 0.354) > Organoids models offer a robust platform for investigating the potential mechanisms of GI diseases and evaluating potential therapeutic interventions.By culturing organoids derived from patients' tissues or stem cells, researchers can delve into disease-specific cellular and molecular pathways, encompassing aberrant cell signaling, perturbed immune responses, and dysfunctional metabolic processes.These disease-specific phenotypes enable the study of disease progression, screening of prospective therapeutics, as well as identification of novel drug targets and mechanisms of action for GI diseases in a clinically relevant context.

[5] Recent advances in modelling of cerebellar ataxia using induced pluripotent stem cells

  • Authors: M. M. Wong, L. Watson, Esther B. E. Becker
  • Year: 2017
  • Venue: Journal of neurology & neuromedicine
  • URL: https://www.semanticscholar.org/paper/0d962652305116e383ab260b9e82d3a5ffe1722f
  • DOI: 10.29245/2572.942X/2017/7.1134
  • PMID: 28825058
  • PMCID: 5558869
  • Citations: 9
  • Summary: This review focuses on recent breakthroughs in generating human iPSC-derived Purkinje cells and highlights the future challenges that will need to be addressed in order to fully exploit these models for the modelling of the molecular mechanisms underlying cerebellar ataxias and the development of effective therapeutics.
  • Evidence snippets:
  • Snippet 1 (score: 0.353) > dominant polyglutamine spinocerebellar ataxias (SCAs) are the most studied forms of ataxias. Despite significant clinical and genetic heterogeneity, emerging evidence points to the existence of common pathogenic mechanisms that may be shared by several genetically distinct forms of cerebellar ataxias (reviewed in5-8). However, it is still unclear how the proposed pathological pathways ultimately result in cerebellar dysfunction and degeneration, predominantly affecting Purkinje cells. > Understanding disease mechanisms is key to treating neurodegenerative disorders. The heterogeneous nature of the cerebellar ataxias combined with the unavailability of human brain tissue and the lack of reliable disease models have, however, hampered our understanding of the molecular disease mechanisms underlying cerebellar ataxias and thus, the development of effective therapies. Although mouse models of several cerebellar ataxias, including FRDA and SCAs, have provided valuable insights into the pathophysiology of these disorders (reviewed in9), many questions remain about the observed species differences in disease phenotypes and the effectiveness of potential drugs in clinical trials. > To help translate research from animal models into novel treatments for ataxia patients, it is essential to validate findings in the relevant affected human cell types, particularly in cerebellar Purkinje cells. The current obstacles might be overcome by exploiting recently developed human induced pluripotent stem cell (iPSC) technology and neuronal differentiation protocols.

[6] New therapeutic targets in rare genetic skeletal diseases

  • Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
  • Year: 2015
  • Venue: Expert Opinion on Orphan Drugs
  • URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
  • DOI: 10.1517/21678707.2015.1083853
  • PMID: 26635999
  • PMCID: 4643203
  • Citations: 37
  • Influential citations: 1
  • Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.352) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[7] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

  • Authors: W. Tulalamba, T. Janvilisri
  • Year: 2012
  • Venue: International Journal of Cell Biology
  • URL: https://www.semanticscholar.org/paper/307cb9186444d9dad6e2e3b53763be0de76de186
  • DOI: 10.1155/2012/594681
  • PMID: 22500174
  • PMCID: 3303613
  • Citations: 93
  • Influential citations: 5
  • Summary: The molecular signaling pathways in the NPC are discussed for the holistic view of NPC development and progression and the important insights toward NPC pathogenesis may offer strategies for identification of novel biomarkers for diagnosis and prognosis.
  • Evidence snippets:
  • Snippet 1 (score: 0.351) > In the pregenomic eras, highly integrated and complex circuitry of molecular signaling in NPC pathogenesis was only partially understood. Over the past decade, the knowledge of the molecular mechanisms in NPC carcinogenesis has been rapidly accumulated. Dysregulation and abnormal protein expression of molecules in certain signaling pathways involved in cellular functions including proliferation, adhesion, survival, and apoptosis has been demonstrated in the NPC cells. Detailed information on the complex network in signaling pathway leading to a coordinated pattern of gene expression and regulation in NPC will undoubtedly provide important clues to develop novel prognostic and therapeutic strategies for this cancer. Refining molecular markers into clinically relevant assays may assist in the detection of NPC in asymptomatic patients, as well as stage classification and monitoring disease progression and treatments. Furthermore, selective regulation of particular proteins targeting cancer cell proliferation, invasion, and apoptosis is a hopeful prospect for future anticancer therapy that slow disease progression and improve survival.

[8] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

  • Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
  • Year: 2020
  • Venue: Current Neuropharmacology
  • URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
  • DOI: 10.2174/1570159X17666191021141057
  • PMID: 31631822
  • PMCID: 7327943
  • Citations: 12
  • Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
  • Evidence snippets:
  • Snippet 1 (score: 0.346) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[9] Modeling psychiatric disorders: from genomic findings to cellular phenotypes

  • Authors: Anna Falk, Vivi M. Heine, A. Harwood, Patrick F. Sullivan, M. Peitz et al.
  • Year: 2016
  • Venue: Molecular Psychiatry
  • URL: https://www.semanticscholar.org/paper/235b41240d78140de7ab06a3ad8a7d0b1bdff1a5
  • DOI: 10.1038/mp.2016.89
  • PMID: 27240529
  • PMCID: 4995546
  • Citations: 77
  • Influential citations: 2
  • Summary: The challenges for modeling of psychiatric disorders, potential solutions and how iPSC technology can be used to develop an analytical framework for the evaluation and therapeutic manipulation of fundamental disease processes are critically reviewed.
  • Evidence snippets:
  • Snippet 1 (score: 0.337) > The key challenge for iPSC-based disease modeling is to identify one or more relevant cellular phenotypes that accurately represent the disease pathophysiology. Increasing numbers of reports have demonstrated that for many diseases specific pathophysiology can be captured in human iPSC-based disease models. These range from cardiovascular disease, 44,45 cancer, 46,47 ocular disease, 48,49 diabetes mellitus 50,51 and neurological disorders of the brain. 52,53 Can the same approach be applied to complex psychiatric disorders? > The problem is that almost all psychiatric disorders are characterized by clinical signs and symptoms, but lack independent verification from objective biomarkers. Thus, how might these clinical phenotypes manifest themselves in terms of cell behavior? The identity of robust cellular 'readouts', which typify any psychiatric disorder, is a crucial unsolved problem and an area of intense study 54 (Table 2). When satisfactorily answered, this will herald a new degree of biological objectivity and quantification for the study of psychiatric disorders. > The aim is to find a single or small number of cell phenotypes or parameters that strongly associate with psychiatric disorders, and establish a cellular profile characteristic of cells derived from the general patient population. Although a consensus set of cellular phenotypes for psychiatric disorder is yet to be established, we can define some of their desired characteristics. First, cellular phenotypes have to relate to the biological pathways identified by genetics. Second, although there are many risk genes in disparate biological pathways, at some level, phenotypes should converge onto a much smaller grouping. Third, phenotypes need to be quantifiable. Finally, to be useful for drug development cellular phenotypes should be reversed by pharmacological treatment, although not necessarily by drugs in current use. > Although human iPSC-based approaches underrepresent the complexity of the human central nervous system, cellular phenotypes are likely to lie more proximal to molecular disease mechanisms than phenotypes seen at the level of a tissue or organism, 55 and thus may bypass compensatory homeostatic (2) Gene expression profiles of SCZ human iPSC neurons identified altered expression of many components of the cyclic AMP and WNT signaling pathways. > (3

[10] Recent Evidences of Epigenetic Alterations in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review

  • Authors: R. Ragusa, Pasquale Bufano, A. Tognetti, M. Laurino, Chiara Caselli
  • Year: 2025
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/2660cdbbe1f205c631fe890e5c6a3c8d9b81ce5f
  • DOI: 10.3390/ijms26062571
  • PMID: 40141213
  • PMCID: 11942187
  • Citations: 4
  • Summary: A systematic review of the latest knowledge on epigenetic modifications that characterize COPD, summarizing epigenetic factors that could serve as potential novel biomarkers and therapeutic targets for the treatment of COPD patients.
  • Evidence snippets:
  • Snippet 1 (score: 0.336) > The papers included were clustered according to epigenetic mechanisms involved in COPD (molecular and cellular processes, as biomarker or therapeutic target). Tables 4-9 describe the extracted information, including the following: Study = name of first author et al., year; Country (Region) = where the study took place; Number of participants = sample size; Type of sample = biological sample employed; Gene affected = gene or group of genes whose expression can be "regulated" by epigenetic mechanisms; Epigenetic alteration = type of epigenetic alteration observed in the presence of disease; Activity in COPD = involvement of epigenetic elements in different molecular and cellular mechanisms associated with COPD; and Role of epigenetic mechanisms = epigenetic modifications that can be used to explain the pathophysiology of COPD or as biomarkers and therapeutic targets.

[11] Chemotherapy and Mechanisms of Resistance in Breast Cancer

  • Authors: A. Oliveira, R. E. Santos, F. F. O. Rodrigues
  • Year: 2012
  • Venue: Unknown venue
  • URL: https://www.semanticscholar.org/paper/502a86d8bcd7208be6f539fcceba631f82f25a7d
  • DOI: 10.5772/24629
  • Summary: The addition of adjuvant polychemotherapy in advanced breast cancer showed gain by controlling survival of micrometastases in patients with lymph nodes affected by cancer or not.
  • Evidence snippets:
  • Snippet 1 (score: 0.336) > The main reasons responsible for treatment failure in cancer patients are the mechanisms of drug resistance and emergence of disseminated disease (Terek et al, 2003). We identified two types of resistance most relevant to BC: primary resistance, which corresponds to the clinical situation where the patient showed no response to therapy, and secondary or acquired resistance in which, initially, there is an observed response and a subsequent failure of the treatment regimen (Kroger et al, 1999). Several mechanisms may cause the phenotype of multidrug resistance to chemotherapy drugs and are well characterized in in vitro experiments, including alterations in systemic pharmacology (pharmacokinetics and metabolism), extracellular mechanisms (tumor environment, multicellular drug resistance), and cellular mechanisms (cellular pharmacology, activation and inactivation of drugs, modification of specific targets and regulatory pathways of apoptosis) (Leonessa et al, 2003, Riddick et al, 2005. Identification of factors that affect cell metabolism, which are related to drug resistance, will enable the identification of which patients are at particular risk of treatment failure. Among the biochemical and molecular mechanisms of drug resistance, we stress: changes in the activity of topoisomerase II, alterations in the DNA repair mechanism, overexpression of P-glycoprotein; high intracellular concentrations of enzymes purification of cellular metabolism -among them enzymes the family of glutathione S-transferases (GSTs) and changes in the mechanisms of signaling via c-Jun N-terminal kinase 1 (JNK1) -and "apoptosis signal-regulating kinase (ASK1) required for activation of the" mitogenactivated protein (MAP kinases) in apoptosis and cellular restoration. These pathways are also mediated by proteins encoded by genes of GSTs (O'Brien, Tew, 1996;Burg, Mulder, 2002, L'Ecuyer et al, 2004). Different response rates to particular chemotherapy regimens, as observed in patient groups with the same biological characteristics and stage, suggest the existence of different mechanisms of drug resistance, probably induced by genetic alterations (Hayes, Pulford, 1995;O'Brien , Tew, 1996;Pakunlu et al, 2003). Among the mechanisms of purification of cellular metabolism involved in the

[12] Role of Transcriptomics in Precision Oncology

  • Authors: Ruby Srivastava
  • Year: 2024
  • Venue: Reports of Radiotherapy and Oncology
  • URL: https://www.semanticscholar.org/paper/0bd862558bbb7286336111d9dfd232b5f905d3d9
  • DOI: 10.5812/rro-142195
  • Citations: 4
  • Summary: : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding o...
  • Evidence snippets:
  • Snippet 1 (score: 0.335) > : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding of cancer and opened a precise perspective for tumor diagnostics and therapy. The use of these approaches has strengthened our understanding of disease pathophysiology and classifications at the molecular level, including specific interference with drug mechanisms of action. Still, it has limited added value in the clinical setting. The omics data on precision medicine include the application of data from genes, transcripts, and proteins for diagnosis, monitoring of diseases, risk factor determination, counseling, and development of novel therapeutics. Bioinformatics applications have expanded statistics-based analysis toward deriving molecular pathways and process models for characterizing phenotypes and drug action mechanisms. In this review, we will discuss transcriptomics and interference analysis that allows the identification of predictive biomarkers at the molecular level to test drug response and analyze the molecular process interface of disease progression-relevant pathophysiology and mechanism of action to propose predictive biomarkers.

[13] Computational modelling of TNFα related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration

  • Authors: Hemalatha Sasidharakurup, Shyam Diwakar
  • Year: 2020
  • Venue: Applied Network Science
  • URL: https://www.semanticscholar.org/paper/aea95bfe3c4303f1361a8ea72828d2926ea0d03e
  • DOI: 10.1007/s41109-020-00307-w
  • Citations: 9
  • Summary: Simulations suggest insulin may be an important factor identifying neurodegeneration in AD and PD, through its action along with the neuroinflammation and oxidative stress.
  • Evidence snippets:
  • Snippet 1 (score: 0.335) > Modelling complex biological pathway networks including their cellular and molecular components, and interactions (Ji et al. 2017) can help connect critical factors statistically relevant as common signaling mechanisms or phentotypic functions to both disorders. Developing computational models can aid reproducing disease pathways and predicting dynamical behaviours essential for approprite protocol design and experimental testing and to map clinical symptoms to molecular processes going through cellular and circuit functions (Conradi et al. 2007;Bartocci and Lió 2016). Using biochemical systems theory (BST), sub-cellular reactions and biochemical pathways were modeled using ordinary differential equations (ODE) for reconstructing signalling dynamics in this study (Savageau et al. 1987). All biochemical reactions involved in disease-related signalling pathways were expressed mathematically using ODE and rate equations were computed using computational tools (Bartocci and Lió 2016). > The objective of this modeling exercise was to map major genes or proteins involved in disease mechanism, the reactions affected by the mutation of these genes and the difference in reactions when compared with healthy controls, action ofpotential drugs. In literature, BST models on oxidative stress and inflammation in insulin resistance were already available for PD condition (Braatz and Coleman 2015). These models explore some of the important pathways involved in PD and the treatment options. Most of the initial conditions for the model parameters were assigned as relative values rather than real data. With the need to model crosstalk and critical networks relevant to neurodegeneration identified by more recent studies, we have incorporated the crosstalk between insulin resistance, oxidative stress and neuroinflammation related to TNFα signalling in normal, AD and PD conditions (Fallahi-Sichani et al. 2011;Sasidharakurup et al. 2020;Su and Wu 2020). The parameteric values relating to biological states and initial conditions for this model were manually extracted from literature on disease models. In a previous study, we had modelled the role of TNFα mediated glutamate excitotoxicity and neuroinflammation (Sasidharakurup et al. 2020) and the variations in TNFα levels during both healthy and diseased conditions were analyzed.

[14] Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation

  • Authors: Hao Xiong, Jinsheng Guo
  • Year: 2025
  • Venue: Pharmaceuticals
  • URL: https://www.semanticscholar.org/paper/76e92127053136900f7e3f10e2c9278251ced5d2
  • DOI: 10.3390/ph18040507
  • PMID: 40283943
  • PMCID: 12030350
  • Citations: 8
  • Summary: HSC-targeted approaches using specific surface markers and receptors may enable the selective delivery of drugs, oligonucleotides, and therapeutic peptides that exert optimized anti-fibrotic and anti-HCC effects.
  • Evidence snippets:
  • Snippet 1 (score: 0.334) > Significant progress has been made in elucidating the cellular and molecular mechanisms of liver fibrosis; however, only a few findings have been successfully translated into clinical applications. Firstly, the high cost of drug development and target validation necessitates prolonged timelines and substantial financial investment. Secondly, as regulatory requirements become more stringent, there is an increasing demand for drugs with well-defined clinical efficacy and safety profiles. Moreover, the efficacy observed in animal models often fails to fully translate to clinical settings due to differences in pharmacokinetics, extracellular matrix (ECM) cross-linking, and disease pathophysiology. Despite advancements in anti-fibrotic drug development, accurately identifying ideal noninvasive biomarkers for fibrotic activity and establishing consensus on optimal clinical endpoints remain significant challenges [113,114]. > Currently, addressing the underlying cause remains the only proven strategy to halt or reverse liver fibrosis progression, while the development of effective anti-fibrotic therapies continues to pose a major challenge in liver disease management. Over the past few decades, substantial progress has been made in elucidating the cellular and molecular mechanisms underlying liver fibrosis. Liver fibrosis is a complex pathological change involving multiple cells, factors, and pathways, and the study of the cellular and molecular mechanisms of its occurrence and development provides an important theoretical basis and therapeutic target for clinical drug development. It is anticipated that improved animal models and well-designed clinical trials will facilitate the successful translation of anti-fibrotic research into effective clinical treatments in the near future.

[15] Massive changes in gene expression and their cause(s) can be a unifying principle in the pathobiology of Alzheimer's disease

  • Authors: P. Coleman, Elaine Delvaux, J. H. Kordower, Ashley Boehringer, Carol J. Huseby
  • Year: 2025
  • Venue: Alzheimer's & Dementia
  • URL: https://www.semanticscholar.org/paper/81c804d9a09df3de462ba1a9c3a1b28c98b021cd
  • DOI: 10.1002/alz.14555
  • PMID: 39912452
  • PMCID: 11851168
  • Citations: 5
  • Summary: Evidence for a unifying model based on sequestrations in stress granules and alteration of nucleocytoplasmic transport in AD is reviewed, with a focus on sequestrations in stress granules and alteration of nucleocytoplasmic transport.
  • Evidence snippets:
  • Snippet 1 (score: 0.333) > The Alzheimer's disease (AD) field has long been fragmented. Over the decades, there have been a series of hypotheses of biological mechanisms in AD including cholinergic (e.g., Davies & Maloney), 1 inflammation (e.g., Akiyama et al.), 2 viral, 3 mitochondrial, 4 protein processing, 5 vascular, 6 tau, 7 and amyloid 8 hypotheses, among others. > None of these hypotheses have led to halting or reversing disease, and there are a number of possible explanations for these failures, including intervention coming too late in disease progression. However, the failures do not have to mean that these hypotheses are wrong. They all deal with real facts in the biology of AD but are limited by each addressing only a portion of the biology of AD. We argue that the total biological complexity of AD is represented in the large number of changes in gene expression that have been described in many studies and represent > 90% of known Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The comprehensive text-mining study of Morgan et al. 9 reported that pathways altered in AD are related to synapses, cell death, inflammation, phagosome, virus infection, metabolic pathways, calcium signaling, transcription, lysosome, long-term potentiation (LTP), protein processing in endoplasmic reticulum (ER), cell cycle, actin, mammalian target of rapamycin pathway, ribosome, Ras pathway, interleukin 17 pathway, RNA polymerase RNA transport, Hippo signaling pathway, and more (see Table S9 in Morgan et al. 9 ). This raises the question of what mechanism(s) may be responsible for the thousand plus changes in gene expression in AD. > In addition to these many gene expression changes in AD, a host of risk factors have also been described for the AD clinical phenotype, including genetic, environmental, and lifestyle factors. How can we link the inputs of risk factors with the outputs of gene expression changes, AD cellular phenotype, and clinical disease? What cellular/molecular mechanism(s) may play a role in the coordinated change in expression of such large numbers of genes in AD?

[16] Microglia Activation in the Brain as Inflammatory Biomarker of Alzheimer’s Disease Neuropathology and Clinical Dementia

  • Authors: Z. Xiang, V. Haroutunian, L. Ho, Dushant P. Purohit, G. Pasinetti
  • Year: 2005
  • Venue: Disease Markers
  • URL: https://www.semanticscholar.org/paper/c67d600b340d2f12afa77ea72927ad5b491a0fca
  • DOI: 10.1155/2006/276239
  • PMID: 16410654
  • PMCID: 3850819
  • Citations: 105
  • Influential citations: 3
  • Summary: The results suggest that microglia activation increases with the progression of AD, with the increase varying depending on the involved brain region.
  • Evidence snippets:
  • Snippet 1 (score: 0.332) > In recent years, a large number of epidemiological studies have addressed the possible protective effect of anti-inflammatory drug use with regard to AD [3]. It is still uncertain however, whether inflammatory mechanisms actually cause damage in AD, or are merely present to remove the debris associated with neurodegenerative events. On a molecular level it is apparent that an inflammatory response accompanies the neu-ropathologic features of AD [1,18] though clinical features of inflammation are absent. The complement system appears to be active in the AD brain [16], with generation of the lytic membrane attack complex [24], and presumably with the release of anaphylatoxins. Upregulation of cyclooxygenase (COX)-2 in neurons as a function of the clinical progression of the AD dementia [9] suggests that inflammatory lipids may also be involved in the pathogenesis of the disease [17]. > As the major cellular mediators of inflammation, microglia have the characteristics of antigen-presenting tissue macrophages, including Human Leukocyte Antigen (HLA)-DR surface markers [11]. HLA-DR expression is found in microglia assuming either a ramified (resting state) or an amoeboid (reactive or activated state) morphology. Microglia may synthesize and secrete β-amyloid (Aβ) [26], as well as produce cytokines [25], nitric oxide and superoxide free radicals [4,5] that may aggravate or promote neurodegeneration. Activated microglia increase in AD patients and also in elderly non-AD controls [11]. Activated microglia and astrocytes have been found in abundance near neuritic plaques (NP) and neurofibrillary tangles (NT) in definitive AD cases [11,21,23]. However, it is unclear how microglia activation evolves in relation to the clinical progression of AD pathology or cognitive status. > In our previous study, we found that up-regulation of neuronal COX-2 protein appeared very early in the clinical progression of AD and preceded the onset of the induction of cytokine gene expression [9,10].

[17] Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

  • Authors: E. Courcelles, J. Boissel, J. Massol, I. Klingmann, R. Kahoul et al.
  • Year: 2022
  • Venue: Frontiers in Medical Technology
  • URL: https://www.semanticscholar.org/paper/877d5b1b75599745f704a9c8371f74601ff17e2f
  • DOI: 10.3389/fmedt.2022.810315
  • PMID: 35281671
  • PMCID: 8907708
  • Citations: 6
  • Summary: Light is shed on different stakeholder's contributions and needs in the appraisal phase and how mechanistic modeling strategies and reporting can contribute to this effort to implement mechanistic models central in the evidence generation, synthesis, and appraisal of HTA so that the totality of mechanistic and clinical evidence can be leveraged by all relevant stakeholders.
  • Evidence snippets:
  • Snippet 1 (score: 0.332) > A second limitation in HTA is the fact that currently population (and sometimes stratified) medicine is pursued during clinical Uncertainty not completely addressed in competent authority assessment report Example use of MIDD relevant to address uncertainty potentially also during HTA What is the optimal dosage in the clinical context? > Physiologically based pharmacokinetic models can investigate dosing-regimens relevant for regulatory review and product labels (9) and can also mimic real-life adherence to prescribed treatment regimens (see also below) or pharmacology-relevant characteristics of special populations as well as drug-drug interactions. > What is the duration of the effectiveness, especially with chronic use of a treatment? > Mechanistic models can predict the long-term disease progression by extrapolation of shorter-term findings under the constraints of how the components of the system function (and these constraints convey biological plausibility by design). An example is the use of a mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin, and gliclazide on disease processes underlying Type 2 Diabetes Mellitus (10). Another example is prediction of long-term outcomes by short-term marker data as demonstrated by a semi-mechanistic approach in context of osteoporosis treatment (11). > What is the efficacy for relevant clinical outcomes? > Mechanistic models combined with pharmacometric approaches can translate findings for one outcome to a range of other outcomes. An example of survival modeling on the back of a mechanistic description is the modeling framework for CD19-Specific CAR-T cell immunotherapy using a quantitative systems pharmacology model (12). > What is the size of the clinical effect dependent on patient characteristics and extrinsic factors? > Data-driven modeling techniques can capture correlation within clinical data. Describing the clinical effect of a drug can also be based on mechanistic considerations. Such models either (a) link disease phenotypes to increasingly granular mathematical representations of pathophysiologic processes (top-down approach) or (b) derive functional, computable cellular networks from the molecular building blocks of genes and proteins to elucidate the impact of pathologic or therapeutic alterations on network operating states and hence clinical phenotype (bottom-up) [

[18] Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells

  • Authors: D. Gurda, L. Handschuh, Weronika Kotkowiak, H. Jakubowski
  • Year: 2015
  • Venue: Amino Acids
  • URL: https://www.semanticscholar.org/paper/0e9ac31119ab67e72fdaa6e9cc442fa7ed2f4642
  • DOI: 10.1007/s00726-015-1956-7
  • PMID: 25802182
  • PMCID: 4458266
  • Citations: 93
  • Influential citations: 3
  • Summary: It is found that each Hcy metabolite uniquely modulates gene expression in pathways important for vascular homeostasis and identify new genes and pathways that are linked to HHcy-induced endothelial dysfunction and vascular disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.331) > lead to the accumulation of Hcy and its metabolites in the blood-hyperhomocysteinemia (HHcy)-which is an independent risk factor for cardiovascular disease (CVD) and causes endothelial dysfunction, a hallmark of atherosclerosis (Dayal and Lentz 2008). However, molecular mechanisms underlying the pathophysiology of HHcy are not fully understood (Jakubowski 2011(Jakubowski , 2013;;Perla-Kajan et al. 2007). One hypothesis states that metabolic conversion of Hcy to Hcythiolactone initiates a pathway that leads to pathologies associated with HHcy (Jakubowski 1997a(Jakubowski , 1999(Jakubowski , 2007)). Hcy-thiolactone is chemically reactive and modifies ε-amino groups of protein lysine residues, which generates immunogenic and toxic N-homocysteinylated protein (N-Hcy-protein) (Jakubowski 2008(Jakubowski , 2013;;Jakubowski et al. 2000). > In humans and mice, HHcy leads to the accumulation of Hcy-thiolactone and N-Hcy-protein, in addition to Hcy (Chwatko et al. 2007;Jakubowski et al. 2008Jakubowski et al. , 2009)). We and other investigators have shown that HHcy induces changes in gene expression in mouse models that are associated with atherothrombotic disease (Devlin et al. 2005;DiBello et al. 2010;Ingrosso et al. 2003;Kim et al. 2011;Pogribny et al. 2008;Sharma et al. 2006;Suszynska-Zajczyk et al. 2014a, b, c, d). However, it is not known what mechanism(s) are involved and which metabolite-Hcy itself, Hcy-thiolactone, or N-Hcy-protein-is responsible for changes in gene expression. > The key to understanding mechanisms by which HHcy disrupts normal cellular function and ultimately causes disease is to identify genes whose expression is affected by individual Hcy metabolites.

[19] Differential metabolic markers associated with primary open-angle glaucoma and cataract in human aqueous humor

  • Authors: C. Pan, Chaofu Ke, Qin Chen, Yijin Tao, Xu Zha et al.
  • Year: 2020
  • Venue: BMC Ophthalmology
  • URL: https://www.semanticscholar.org/paper/a22a466f72ee8f8a5808f51c7000ff38b8b60b04
  • DOI: 10.1186/s12886-020-01452-7
  • PMID: 32375707
  • PMCID: 7203853
  • Citations: 26
  • Influential citations: 1
  • Summary: This study identified valuable metabolic biomarkers and pathways that may facilitate an improved understanding of the POAG pathogenesis and hold translational value in the development of new therapeutic measures for POAG.
  • Evidence snippets:
  • Snippet 1 (score: 0.330) > Primary open-angle glaucoma (POAG) is the most common subtype of glaucoma and the major cause of irreversible blindness throughout the world [1]. Although numerous studies have identified several important ocular risk factors for POAG such as increased intraocular pressure (IOP) [2,3], myopic refractive errors [4], larger optic disc size [5,6] and thinner central corneal thickness [7,8], these findings are limited in understanding the pathophysiology of POAG. Further knowledge regarding the pathophysiology might help to create new drug development research lines and expand current therapeutic targets for POAG. In current clinical practice, the treatment strategy of POAG mainly relies on IOP-lowering medications or surgeries. Although increased IOP is widely accepted to be the primary predictor for POAG, glaucomatous neuropathy is still observed in some patients with normal or even lower-than-normal IOPs, suggesting that other mechanisms exist in the pathophysiology of POAG. > Metabolomics is a widely used technology to assess biomarkers for diseases and provide molecular information regarding disease phenotype since metabolites are the ultimate product of gene, mRNA and protein activities [9]. Variations in the metabolome represent the interplay of genetic and environmental factors and are in relation to disease states, which may shed some lights in mechanism and pathophysiology of the disease [10]. With regard to eye diseases, metabolomics has been successfully used in identifying the metabolic signatures of diabetic retinopathy [11]. However, there were less studies focusing on POAG, especially in human participants. A previous analysis comparing plasma metabolic signatures as measured by mass spectrometry observed significant differences in some specific metabolic processes such as palmitoylcarnitine, sphingolipids, vitamin Drelated compounds, and steroid precursors between POAG patients and healthy controls [12]. These differences observed in metabolome might be linked to mitochondrial dysfunction and energy metabolism changes [12].

[20] LifeTime and improving European healthcare through cell-based interceptive medicine

  • Authors: N. Rajewsky, G. Almouzni, S. Gorski, S. Aerts, I. Amit et al.
  • Year: 2020
  • Venue: Nature
  • URL: https://www.semanticscholar.org/paper/d626a4acb560c1ef16ea394cb4dccf277882d119
  • DOI: 10.1038/s41586-020-2715-9
  • PMID: 32894860
  • PMCID: 7656507
  • Citations: 138
  • Influential citations: 2
  • Summary: The LifeTime initiative is an ambitious, multidisciplinary programme that aims to improve healthcare by tracking individual human cells during disease processes and responses to treatment in order to develop and implement cell-based interceptive medicine in Europe over the next decade.
  • Evidence snippets:
  • Snippet 1 (score: 0.328) > , a major challenge is a lack of understanding of the early events in disease onset to enable the development of disease-modifying therapies. The lack of access to longitudinal samples from patients necessitates the establishment of cohorts of patient-derived disease models to understand the cellular heterogeneity associated with disease. The discovery of pathways and biomarkers that will allow the stratification of patients on the basis of the cellular mechanisms that drive a disease will make it possible to design new clinical trials to reevaluate drugs that were previously tested without such stratification, and to broaden the drug target portfolio. > As seen during the coronavirus disease 2019 (COVID-19) pandemic, it is important to be able to understand infection mechanisms and the host response in order to rapidly identify the most likely effective treatment for an infection. At the same time, the continuous rise of antimicrobial resistance requires the discovery of new therapeutic strategies. A key medical challenge for infectious diseases is to understand the cellular response to infections and to develop precision, immune-based therapeutic strategies to combat infections. > Chronic inflammatory diseases impose a high burden owing to their long-term debilitating consequences, which result from the structural destruction of affected organs or tissues. Current therapies treat the symptoms but do not cure or fully control the chronic inflammatory pathophysiology. While different targeted therapies exist, they are expensive and their success is limited by high rates of non-response to treatment. Consequently, there is an urgent need to explore and understand how cellular heterogeneity contributes to the pathology of inflammatory diseases 61 and how this relates to the predicted course of disease and the response of a patient to one of the numerous available therapies. > Many cardiovascular and metabolic diseases lack effective therapies owing to a lack of knowledge of their underlying causes and the link between abnormal cardiac cell structure or function and pathophysiology. The identified medical priority is to understand the cellular and molecular mechanisms involved, in order to enable early diagnosis and the design of new mechanism-based therapies for precise clinical treatment. > The LifeTime disease roadmaps can be divided broadly into three phases 7 : first, immediate research into the identified medical challenges using established, scaled single-cell technologies, computational tools and disease models; second, the development of new technologies that are required

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.